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Chapter 1
Breast cancer is the most frequent tumor in women and the incidence is 
still rising [1]. In the Netherlands, one in 8-9 women will get this disease and 
over 13.000 new cases of breast cancer are diagnosed each year [2]. Because 
of early detection, intervention, and postoperative treatment, breast cancer 
mortality has been decreasing [3]. Traditional treatment of cancer generally 
consists of surgical excision of the tumor and surrounding tissue followed by 
chemotherapy and/or radiation therapy.
Mammography plays a major role in early detection of breast cancers and is 
a good screening tool for breast cancer. The sensitivity of mammography in 
women aged over 50 has been estimated to range from 68% to over 90%. In 
women aged 40-49 the sensitivity has been reported to be lower, with estimates 
between 62% and 76% [4]. Mammography is less effective in identifying cancers 
in women under 50 because breast tissue tends to be denser in pre-menopausal 
women. The sensitivity of mammography is much lower in women with dense 
breasts than those with predominantly fatty breasts [5]. Furthermore, cancers 
found in younger women tend to be more aggressive and grow faster [6-8]. 
Another problem is the relatively low positive predictive value of mammography. 
Only a small fraction of abnormalities that are detected by screening 
mammography and subsequently subjected to biopsy examination result in a 
diagnosis of cancer. The low positive predictive value of mammography means 
that a large proportion of breast biopsies will be performed on lesions or other 
mammographic abnormalities that turn out to be benign, which leads to a 
high number of unnecessary biopsies. Findings at screening mammographic 
examinations have a lower change of malignancy (PPV for mass, 9.7%; PPV for 
calcifications, 12.7%; PPV for architectural distortion, 10.2%; PPV for asymmetry, 
3.7%) than do findings at diagnostic mammographic examinations (PPV for 
mass, 19.6%; PPV for calcifications, 24.1%; PPV for architectural distortion, 
60.2%; PPV for asymmetry, 14.6%) [9].
The role of ultrasound in breast imaging is limited to the evaluation of lesions 
detected by other image modalities or clinical examination. Due to the fact that 
it is very operator dependent and time consuming, ultrasound has currently 
little value in screening for breast cancer [10]. Its main strengths are the ability 
to distinguish solid from cystic lesions, to aid in the evaluation of the axilla for 
enlarged lymph nodes and it is very useful to guide biopsies or localizations. 
Magnetic resonance imaging (MRI) creates detailed images of the breast using 
a computer and powerful magnets. Breast MRI is a very useful exam and should 
be used in certain patient groups (high-risk women (with BRCA-1 or BRCA-2 
gene mutations and/or a strong family breast cancer history), chemotherapy 
patients or sometimes in inconclusive mammogram or ultrasound) because of 
the low specificity (range from 67% to 77% [11]) and high cost. In some MRI
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tests, the patient is injected with a contrast material to help the technologist 
identify certain parts of the body/breast.
Women will be lie down on their stomach on an examination table and the breasts 
will be hanging down into cushioned openings, after an IV line is established to 
allow injection of contrast material (gadolinium) during the scan. The openings 
are surrounded by a breast coil. This coil receives the signals that work with 
the MRI device to take the images before and after contrast material injection. 
Breast cancers typically have a rich blood supply, so tumors "light up" on MRI on 
the dynamic series. The most widely used form of dynamic contrast enhanced 
MRI analysis is the assessment of the type of time-signal intensity curve (i.e., 
kinetic curve) by categorizing the washout pattern of a gadolinium contrast 
agent. Essentially there are two phases in the dynamic contrast enhancement 
MRI observation. First there is the 'initial peak' phase which happens early in the 
process (under two minutes generally). The radiologist will be watching to see 
how high or 'intense' the signal (the 'brightness') reaches within the suspicious 
breast lesion. Once this initial 'peak' is reached, the second phase begins. This 
is the 'delayed' phase. There are three basic patterns and classified as type I, 
persistently enhancing (progressive), which is suggestive of benignity; type II, 
plateau type, which has an intermediate probability for malignancy; and type
III, washout type, which is indicative of malignancy (Figure 1).
Tim e
Figure 1 . Kinetic descriptions (phases) of contrast enhancement.
The use of MRI for the detection and evaluation of breast lesions continues 
to increase. With a sensitivity of around 90% it is a more sensitive method 
than mammography or ultrasound. Approximately 10 - 20% of patients with
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a malignant breast lesion detected on mammography has an additional 
malignancy (multifocal disease) that is mammographically and ultrasonically 
occult [12-14], which can be detected on MRI. Therefore, this can be an 
important additional imaging technique.
Breast MRI at 3T
MRI systems operating at high magnetic fields strengths (e.g. 3 testa (T)) are 
becoming increasingly available in the clinical setting. When compared with 
more standard protocols at 1.5T, breast MRI at a 3T magnetic field strength 
provides several opportunities for improving diagnostic image quality. At 3T, 
breast MRI also opens new paths for investigating novel techniques. By doubling 
the magnetic field strength, the signal-to-noise ratio (SNR) approximately 
doubles (contingent on the coil efficiencies being the same and ignoring 
relaxation effects). In practice, with a finite repetition time (TR), the SNR gains 
are <2. Overall, the SNR gain at 3T allows for potential improvements over the 
1.5T protocol in image resolution and faster data collection. In addition, the 
greater spectral dispersion of fat and water at 3T may improve and/or reduce 
the duration of fat-saturation pulses. In addition, at 3T, exploratory techniques 
such as spectroscopic imaging and blood-oxygen-level-dependent (BOLD) 
contrast imaging become more feasible [15]. One study showed advantage of 
3T over 1.5T breast MRI in lesion detection and classification [16]. Comparison of 
the results in literature between 1T / 1.5T MRI and 3T MRI shows that the 3T MRI 
may have an even higher sensitivity in the detection of breast cancer with no 
significant difference in specificity [17]. Thus, also at 3T it is not always possible 
to separate malignant from benign findings purely on imaging characteristics.
Computer-aided diagnosis (CAD)
The low specificity and the significant time required for image processing and 
interpretation are the major limitations of breast MRI. Also, the level of experience 
and the number of radiologists trained in breast MRI are not yet as high as for 
conventional mammography. A particular challenge for interpretation of breast 
MR images is the assessment of a lesion's morphologic and kinetic features at 
multiple imaging series. To address some of the impediments to performing 
breast MR imaging, computer-aided evaluation programs for MR imaging of 
the breast have been developed [18, 19]. These programs have the potential to 
make breast MRI more efficient and accurate and reduce the number of false- 
positive diagnoses [20]. Such programs are now used by many practice sites
12
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to automatically perform image processing and analysis functions that were 
typically performed manually by the technologist and the radiologist. One key 
analysis function performed with computer-aided diagnosis (CAD) is automatic 
kinetic assessment which can color codes the three basic curve patterns for the 
radiologists' evaluation. The detailed information on lesion kinetics provided 
with computer-aided evaluation differs substantially from that obtained with 
conventional manual placement of a region of interest (ROI). While manual 
placement of a region of interest provides kinetic information only for portions 
of a given lesion, CAD generates detailed data for all pixels in the lesion. 
Analyses of morphological features are left to the radiologist, and then all 
information needs to be integrated by the radiologist to make a final diagnostic 
impression. Therefore, these commercial systems are in fact "computer-aided 
display systems', not a true CAD that gives an intellectual impression about the 
suspiciousness level of the lesion. However, they do provide a very efficient way 
to extract the most essential information. The first published results suggest 
that the quantitative diagnostic features can be used for developing automated 
breast CAD for mass lesions to achieve a high diagnostic performance, but more 
advanced algorithms are needed for diagnosis of lesions presenting as non­
mass-like enhancement [21]. Further efforts to add capabilities for quantitative 
characterization of morphological features into the CAD systems might be 
helpful to increase the specificity.
MRI-guided biopsy
When a suspicious lesion is identified on MR imaging, every effort should be 
made to re-identify the lesion on conventional modalities such as mammography 
or ultrasound [22]. If the lesion can be clearly identified on mammography or 
ultrasound, biopsy should be performed using one of these guiding modalities, 
because of patient comfort, the duration of the examination and cost. Moreover 
patients usually tolerate ultrasound guided biopsy better than MRI-guided 
biopsy (more or less like mammography-guided biopsy). However, second-look 
ultrasound fails to identify any ultrasonic correlate in as many as 44% of MRI 
detected lesions referred for biopsy [23, 24]. When suspicious breast lesions are 
detected on MR images solely histopathologic analysis is required. MRI-guided 
tissue sampling of these "MRI-only lesions' can be accomplished by means 
of wire localization and surgical excision, large core-needle biopsy (LCNB) or 
vacuum assisted biopsy (VAB) [25].
13
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MRI-guided wire localization
A variety of techniques for MRI-guided wire localization followed by surgical 
excision biopsy have been described in the literature, including stereotactic 
localization with the patient in a supine or prone position [26-34], or a freehand 
localization technique with the patient in a prone position. The "freehand" 
technique has several potential advantages compared with the technique were 
perforated compression plates are used. It is a simple technique and allows 
needle placement with a freely chosen insertion angle, enabling localization 
of lesions throughout the breast, including lesions in the retroareolar region, 
lesions localized close to the thoracic wall, and lesion in patients with silicone 
implants [30].
MRI-guided large core-needle biopsy (LCNB)
MRI-guided LCNB has several advantages over wire localization, including 
decreased invasiveness, morbidity, and costs [35, 36]. A 1.5T MRI-guided LCNB 
is considered both safe and accurate, with published reports of a high rate 
of technical success (95% - 100%) and cancer yields (20% - 38%) comparable 
with the accepted rates reported in mammography and ultrasound-guided 
procedures [25]. Unfortunately, the current equipment for MR-guided biopsy is 
better suited for intervention at 1.5T than 3T due to the potential heating of the 
titanium co-axial sleeves and the larger susceptibility artifacts that results from 
the use of these sleeves.
MRI-guided vacuum assisted biopsy (VAB)
Under mammographic guidance, VAB has proven to be more effective than 
LCNB [37, 38]. The certainty of the histopathologic diagnosis increases with the 
amount of tissue extracted, especially in a situation where there is no real-time 
feedback of the needle position during biopsy, as is the case of MRI-guided 
breast biopsy. Using a 1.5T MRI scanner, articles have reported a technical 
success rate of 95% to 100% and cancer yields ranging from 24% to 40% for 
MRI-guided VAB, which is comparable with the results of MRI-guided LCNB at 
1.5T [32]. The use of VAB has also allowed accurate targeting of lesions smaller 
than 10mm [39].
Nevertheless none of these techniques had been tested at 3T when the research 
of this thesis was started.
14
General introduction
Thesis outline
The principal goal of this thesis is to increase the certainty of the (histopathologic) 
diagnosis of MRI detected lesions.
Therefore, it was tested whether the specificity of breast MRI at 3T could be 
improved with the use of a CAD system in order to try to reduce the number of 
unnecessary biopsies of MR only detected lesions.
Nevertheless for a certain diagnosis histopathology is often essential since even 
with sophisticated methods a certain diagnosis is often not obtainable with 
imaging alone. Hence, for optimizing the certainty of diagnosis it is essential 
to find the optimal biopsy technique at 3T. To reach this goal we investigated 
several different biopsy techniques (wire localization followed by surgical 
excision, LCNB and VAB) at 3T.
In chapter 2 we compare the consistency between and accuracy of manual and 
fully automated kinetic analyses in the interpretation of 3T breast MRI. CAD data 
sets were interpreted by two experienced breast radiologists and two residents. 
For each lesion automated analysis of enhancement kinetics was evaluated at 
50% and 100% thresholds.
In Chapter 3 we describe 3 cases, women in whom breast MRI revealed 
ultrasonically occult lesions. In these women, MRI-guided needle localization 
of the lesion, followed by surgical excision biopsy or MRI-guided large-core 
needle biopsy was performed. The different techniques are explained in Dutch 
in this chapter.
In Chapter 4 we report our experience with MRI-guided needle localization of 
suspicious breast lesions located in regions of the breast which are difficult to 
access, using the freehand technique in a 3 T closed bore magnet.
In Chapter 5 we describe the feasibility of 3T MRI-guided LCNB of suspicious 
non-palpable breast lesions.
In chapter 6 a dedicated 3T LCNB set that uses plastic coaxial needles instead of 
the titanium sleeves we used in the previous study are evaluated to overcome 
the problems of large susceptibility artifacts at higher field-strength.
In chapter 7 a MRI-guided VAB technique is described. The advantages of VAB 
include a single probe insertion with directional sampling and rapid collection 
of larger samples. In this study we evaluated MRI-guided LCNB and VAB using 
a 3T scanner and compared the diagnostic yield and rate of complications to 
determine the optimal biopsy technique.
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Abstract
Objective
The purpose of the study was to evaluate the accuracy of 3T breast MRI 
interpretation using manual and fully automated kinetic analyses.
Material and methods
Manual MRI interpretation was done on an Advantage Workstation. 
Retrospectively, all examinations were processed with a computer-aided 
detection (CAD) system. CAD data sets were interpreted by two experienced 
breast radiologists and two residents. For each lesion automated analysis of 
enhancement kinetics was evaluated at 50% and 100% thresholds. Forty-nine 
malignant and 22 benign lesions were evaluated.
Results
Using threshold enhancement alone, the sensitivity and specificity of CAD 
were 97.9% and 86.4%, respectively, for the 50% threshold, and 97.9% and 
90%, respectively, for the 100% threshold. Manual interpretation by two breast 
radiologists showed a sensitivity of 84.6% and a specificity of 68.8%. For the 
same two radiologists the mean sensitivity and specificity for CAD-based 
interpretation was 90.4% (not significant) and 81.3% (significant at p < 0.05), 
respectively. With one-way ANOVA no significant differences were found 
between the two breast radiologists and the two residents together, or between 
any two readers separately.
Conclusion
CAD-based analysis improved the specificity compared with manual analysis of 
enhancement. Automated analysis at 50% and 100% thresholds showed a high 
sensitivity and specificity for readers with varying levels of experience.
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Introduction
The use of MRI for the detection and evaluation of breast lesions continues to 
increase. With a sensitivity of around 90% it is a more sensitive method than 
conventional mammography or ultrasound for the detection of breast cancer 
[1]. A recent meta-analysis showed the pooled-weighted specificity to be 72%, 
with a 95% confidence interval of 67-77% [1]. An added drawback of breast 
MRI is the significant time needed for image processing and interpretation. 
Also, the experience level and number of radiologists trained in breast MRI is 
not yet as high as for conventional mammography. Computer-aided detection 
(CAD) algorithms have been developed that automate processing and analysis 
functions usually performed manually by MRI technologists and radiologists. 
These systems have the potential to improve efficiency of breast MRI and to 
reduce the number of false-positive diagnoses [2]. Automation may improve 
consistency and detection rate, but also provides new analysis methods, such 
as kinetic curve threshold, that are not available with manual interpretation. 
Compared with 1.5 T, current MRI systems operating at 3T offer a higher signal- 
to-noise ratio and allow higher spatial resolution imaging without affecting 
overall image acquisition time or the temporal resolution of the dynamic 
contrast-enhanced series [3].
This study was performed to compare the consistency and accuracy of 3T breast 
MRI interpretation, between manual and fully automated kinetic analyses.
Materials and methods
Retrospective inclusion of patients and lesions
We retrospectively analyzed the data from a total of 426 consecutive women 
who underwent contrast-enhanced high-spatial-resolution 3.0-T breast MRI at 
our hospital, between May 2005 and December 2006. We chose this time period 
because at that time our hospital replaced the manual kinetic analysis system 
with a fully automated computer-aided detection (CAD)-based kinetic analysis. 
In this way, the data from all patients included in this study were analyzed on 
both systems. No approval by the ethics board or informed consent was needed 
because breast MRI was not performed in a study setting, but in the clinical 
setting.
Women who underwent breast MRI not for clinical indications but for research 
purposes were excluded from this study (n = 71). In addition, 286 patients 
were excluded because histology was not obtained. Of the 69 patients in 
whom histology was obtained, 4 patients with 5 lesions were excluded for 
technical reasons: severe patient motion (n = 2), failed fat suppression (n = 1)
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and a technical error with contrast material injection (n = 2), which caused an 
incomplete study. Finally 65 patients were included with a total of 71 breast 
lesions proven surgically or by core biopsy. The evaluation of the accuracy of 
CAD threshold enhancement was based on these 65 patients. The evaluation 
of the diagnostic accuracy of the four different readers was based on the 
same data set, with the exclusion of all 29 BI-RADS category 6 known cancers. 
Exclusion of known cancers was necessary because readers were blinded to the 
pathological results but not to patient history (Figure 1).
Figure 1 . Flow chart of patient inclusion, with reasons for exclusion and total number of patients 
for each analysis method
Breast MRI: technique
MRI was performed on a 3T MR system (Achieva, Philips Medical Systems, Best, 
the Netherlands). Patients were placed in the prone position on a dedicated 
phased-array bilateral breast coil (MRI devices, Wurzburg, Germany). Transverse 
high-resolution T1-weighted fast field echo (T1-FFE) images were obtained (TE/ 
TR 1.7/4.5 ms; inversion delay SPAIR 130 ms; flip angle 10°; FOV 340 X 340 mm2, 
acquired voxel size 0.66 X 0.66 X 1.6 mm3, reconstructed voxel size 0.66 X 0.66 
X 0.80 mm3), followed by transverse T2-weighted fat-suppressed images (TE/TR
24
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120/9,022 ms; inversion delay SPAIR 125 ms; flip angle 90°; FOV 340 X 340 mm2, 
acquired voxel size 1.01 X 1.31 X 2.0 mm3, reconstructed voxel size 0.66 X 0.66 
X 2.00 mm3). Dynamic fat-suppressed T1-weighted gradient echo images 
were acquired before and immediately after intravenous administration of 
0.1 mmol/kg gadopentate (Magnevist, Schering, Germany) (TE/TR 1.3/3.4 ms; 
flip angle 10°; FOV 320 X 320 mm2, acquired voxel size 0.91 X 0.91 X 2.00 mm3, 
reconstructed voxel size 0.83 X 0.83 X 1.00 mm3; temporal resolution of 60 s 
per dynamic acquisition, with a total of 6 dynamic acquisitions; finally, a post­
gadolinium T1-weighted gradient echo series (TE/TR 1.7/4.5 ms; inversion delay 
SPAIR 130 ms; flip angle 10°; FOV 340 X 340 mm2, acquired voxel size 0.66 X 0.66 
X 1.60 mm3, reconstructed voxel size 0.66 X 0.66 X 0.80 mm3).
Breast MRI interpretation and data collection
Breast MR interpretation using manual kinetics analysis was done on an 
Advantage Workstation (Philips Viewforum, Best, the Netherlands), which 
allows assessment of enhancement kinetics by manual region-of-interest (ROI) 
placement. Studies were read by one of two experienced breast radiologists 
who were blinded to the pathological results. For each MRI-detected lesion, 
a separate American College of Radiology (ACR) BI-RADS-MRI Lexicon 
Classification Form [4] was filled out. In addition, for each lesion the maximum 
size in two orthogonal directions was measured.
All MRI examinations were subsequently processed by CADstream (Confirma, 
Inc., Kirkland, WA), a commercially available computer-aided detection system. 
With CADstream, areas of enhancement that meet a user-defined minimum 
threshold for initial enhancement are automatically identified by color overlays 
on all MRI slices. This initial enhancement threshold refers to the minimum 
increase in signal intensity on the early post-contrast-images over the pre­
contrast images, within the same dynamic series. In addition to indicating the 
degree of initial enhancement, the color overlay allows differentiation between 
persistent-, plateau- and washout-type enhancement in the late phase after 
contrast injection.
CADstream data sets were interpreted by the same two breast radiologists. 
In addition the data sets were interpreted by two residents. The two breast 
radiologists are both registered breast radiologists and have more than 
15 years' experience in breast ultrasound and conventional mammography. 
Both radiologists also have more than 5 years' experience in breast MRI. The first 
residents was in his third year and had 6 months' experience in conventional 
mammography, breast ultrasound and breast MRI, by the time this study took 
place in our hospital. The second resident was in her first year and only had
2 months of experience in conventional mammography and breast ultrasound.
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She had only little experience in breast MRI, by following a 4-day course in 
breast MRI. All of the readers were blinded to the patient's history, treatment 
and pathological outcome, and to the results of the initial interpretation using 
manual enhancement kinetics. CAD reading was done 6 months after manual 
analysis of the same data set. The interval was felt to be long enough to prevent 
the readers from remembering the details of the initial manual kinetic analysis. 
All readers were familiar with the BI-RADS classification system. Separate BI- 
RADS-MRI score sheets were again filled out for all MRI-detected lesions, by all 
individual readers.
Lastly, lesions were scored based on CAD threshold analysis alone, first on the 
basis of a 50% threshold of initial enhancement and subsequently on the basis 
of a 100% threshold of initial enhancement.
Statistical analysis
Statistical analysis was done with SPSS 12.0. Significance was assumed at a level 
of p < 0.05. The interobserver differences in the evaluation of quality criteria were 
evaluated by the paired Student's t test. One-way analysis of variance (ANOVA) 
was used to test for differences among the two experienced breast radiologists 
and the two residents together, or between any two readers separately with the 
use of CAD.
According to the American College of Radiology ACR guidelines, which suggest 
follow-up for "probably benign" lesions (BI-RADS category 3) and consideration 
of biopsy for "suspicious" lesions (BI-RADS category 4), sensitivity and specificity 
according to BI-RADS score were defined as follows:
Numbers of PA - proven malignant lesions with BI - RADS score 4 or 5
Sensitivity BI - RADS = --------------------------------------------------------------
Number of PA - proven malignant lesions
Numbers of PA - proven benign lesions with BI - RADS rating < 3
Sensitivity BI - RADS = --------------------------------------------------------------
Number of PA - proven malignant lesions
where PA refers to pathology.
Results
Patients and lesions
The mean age of the included patients was 49 years (range, 29-71 years). 
Indications for undergoing MRI (Table 1) were: evaluation of indeterminate 
mammographic and/or ultrasound findings (46%); staging of recently 
diagnosed breast cancer (45%); and high-risk screening (20%). Five patients had 
two indications and one patient had three indications.
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Table 1 . Indication for MRI examination in 65 patients
Number
High-risk screening 13 (20%)
Positive family history 7
History of high-risk lesion or cancer 6
Problem solving 30 (46.2%)
Palpable abnormality 6
Questionable lesion mammogram/US 23
Positive axillary node, unknown primary 1
Staging of known breast cancer 29 (44.6%)
Lesion characteristics
Lesions consisted of a focal (8.5%), mass (77.7%), or non-mass-like enhancement
(13.8%). Size ranged from 4 to 49 mm. Histopathological evaluation after
core-needle biopsy or surgical excision revealed 22 benign (including high-
risk) lesions and 49 malignant lesions. Of the 22 benign lesions, 9 (13%) were
fibroadenoma, 6 (8%) showed focal fibrocystic change, 1 (1%) was a benign
complex cyst, 1 (1%) was a lymph node, and 5 (7%) were lobular carcinoma in
situ (LCIS) (Table2).
Table 2 . Histopathologic findings in 71 breast lesions
Number
Malignant lesions 49 (69%)
Invasive ductal carcinoma 15
Infiltrating lobular carcinoma 7
Invasive ducto-lobular carcinoma 2
Pure ductal carcinoma in situ (DCIS) 7
Combination of DCIS and invasive carcinoma 14
Small cell carcinoma 4
High-risk lesions 5 (7%)
Lobular carcinoma in situ 5
Benign lesions 17 (23.9%)
Fibrocystic change 6
Fibroadenoma 9
Lymph node 1
Benign cyst 1
Total 71
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Of the 49 malignant lesions, 24 (34%) were invasive carcinoma (15 invasive 
ductal carcinoma, 7 invasive lobular carcinoma and 2 invasive ducto-lobular 
carcinoma), 7 (10%) were pure ductal carcinoma in situ (DCIS), 14 (20%) were 
a combination of in situ and infiltrating carcinoma, and 4 separate lesions in a 
single patient turned out to be metastases from small cell lung cancer (Table2). 
Table 3 summarizes the sensitivity and specificity for interpretation with 
manual analysis of enhancement kinetics and for interpretation with CAD- 
based analysis enhancement kinetics. Sensitivity and specificity based on CAD 
threshold analysis alone are summarized in Table 4.
Table 3. Sensitivity and specificity of 42 lesions (benign n = 16, malignant n = 26)
Sensitivity Specificity
Radiologist; manual 84.6% (n = 22) 68.8% (n = 11)
Radiologist 1; CAD 88.5% (n = 23) 75.0% (n = 12)
Radiologist 2; CAD 92.3% (n = 24) 87.5% (n = 14)
Residents 1; CAD 88.5% (n = 23) 93.8% (n = 15)
Resident 2; CAD 84.6% (n = 22) 81.3% (n = 13)
Table 4. Sensitivity and specificity of 71 lesions at threshold enhancement at 50% and 100% (benign 
n = 22, malignant n = 49)
Sensitivity Specificity
CAD 50% 97.9% 86.4%
CAD 100% 97.9% 90.0%
Manual interpretation showed a sensitivity of 84.6% and a specificity of 68.8%. 
For the same two radiologists the mean sensitivity and specificity for CAD-based 
interpretation was 90.4% and 81.3%, respectively. This difference in specificity 
was significant at p < 0.05. Between all four CAD readers the sensitivity varied 
from 84.6% to 92.3% and the specificity varied from 75.0% to 81.3%. By one­
way ANOVA no statistical significant difference was found in our study between 
the two experienced breast radiologists and the two residents together, or 
between any two readers separately with the use of CAD (Table 3).
Using threshold enhancement alone, the sensitivity and specificity of CAD were 
97.9% and 86.4% for the 50% threshold, respectively, and 97.9% and 90% for 
the 100% threshold, respectively (Figure2 and Table 4).
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Figure 2. Flow chart of threshold enhancement at 50% and 100%
Discussion
We found that interpretation with CAD-based analysis for enhancement kinetics 
significantly improved the discrimination of benign from malignant lesions 
compared with interpretation with manual analysis of enhancement kinetics. In 
our study initial enhancement was below 50% in 86% of benign lesions. These 
results are in keeping with the findings of Williams et al. [5]. Other authors also 
described an increase in specificity of using CAD that is based on excluding 
lesions with low threshold enhancement [6-11].
Difference in specificity between MR interpretation on an AdvantageWorkstation 
with manual assessment of enhancement kinetics and CAD may also partly 
be explained by the fact that CAD provides enhancement information for all 
pixels in a lesion rather than for a portion of a lesion measured by using manual 
region-of-interest placement [5].
Using threshold enhancement alone, the sensitivity of CAD is high for both 
the 50% threshold and 100% threshold. There was only one malignant lesion 
that was false negative at CAD and did not demonstrate enhancement at the 
50% and 100% thresholds. This lesion was described by three readers as a 
lobular-shaped mass with irregular margin and heterogeneous enhancement. 
One reader described this lesion as a round-shaped mass with regular margin 
and heterogeneous enhancement. Placing a manual ROI showed a malignant 
curve (Figure 3). Three out of the four readers classified this lesion as a BI-RADS 
5 lesion, highly suggestive of malignancy, and one reader as a BI-RADS 4 lesion, 
suspicious. Histopathological evaluation revealed an invasive ductal carcinoma. 
There are some technical limitations to the CAD program that can cause 
negative enhancement at malignant lesions which underscore the importance 
of using CAD as a complement to but not as a replacement for the radiologist's 
assessment [5].
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Figure 3. Example of a lesion that was not colour-coded by CAD as possibly malignant, because 
the absolute pre-contrast signal intensity was determined to be "too low”. Manual analysis 
revealed a washout-type curve for this lesion, with positive threshold-enhancement at both 50% 
and 100%. Pathology showed an invasive ductal carcinoma
Three benign lesions had positive enhancement at a 50% threshold and two of 
these lesions had positive enhancement at 100%. The lesion that had positive 
enhancement at 50% threshold and negative enhancement at 100% threshold 
consisted of normal tissue at histopathological evaluation. Two readers 
classified this lesion as a BI-RADS 3 lesion, probably benign (one resident and 
one radiologist), and the other two readers classified this lesion as a BI-RADS
2 lesion, benign. The two false-positive lesions with positive enhancement at 
the 50% and 100% thresholds revealed one lobular carcinoma in situ and one 
fibroadenoma. Two readers classified the fibroadenoma (Figure 4) as a BI-RADS
3 lesion, one as a BI-RADS 2 lesion and one as an BI-RADS 4 lesion. Lobular 
carcinoma in situ (Figure 5), a high-risk lesion, was twice classified as a BI-RADS
3 lesionand twice as a BI-RADS 4 lesion.
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Figure 4. Example of a false-positive finding. CAD analysis of this lesion (the lesion in red and 
yellow on the left image) indicated positive enhancement at the 50% and 100% thresholds. 
The image on the right is the same lesion in the same slice without the colour-coded overlay. 
Pathology revealed a benign fibroadenoma
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Figure 5. Example of a false-positive finding. CAD analysis of this lesion (the yellow lesion in 
the right breast) indicated positive enhancement at the 50% and 100% thresholds. Pathology 
revealed a lobular carcinoma in situ, a high-risk lesion.
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In our study the readers were not blinded to the results of other imaging 
examinations such as mammography, ultrasound and previous MRI findings. All 
readers had access to patient history and clinical information, i.e. similar to the 
normal clinical setting. In the study by Kurz et al. who compared three different 
software systems in the evaluation of breast MRI, all three investigators were 
blinded to this information [10].
Our study had several limitations. Time needed to fully assess one MRI 
examination of the breast was not objectified as in the study of Kurz et al. [10]. 
They describe an average time needed to evaluate each exam of 7.0 min. Wiener 
et al. reported that most cases were interpreted with the use of an automatic 
post-processing program which generated color parametric maps as well in less 
than 5 min [9]. Although not objectified, the two breast radiologists reported 
shorter interpretation times with CAD assistance than with manual analysis. 
Another limitation is that manual interpretation was not repeated by the two 
residents. Meinel et al. showed that inexperienced readers without the use of 
CAD assistance performed as expected for their level of experience and that 
these differences became less pronounced with the use of CAD assistance [11]. 
In our study, no significant differences were found between the two experienced 
breast radiologists and the two residents together, or between any two readers 
separately with the use of CAD.
With respect to interpreting the very high sensitivities reported here for CAD- 
based analysis based solely on the thresholding of enhancement kinetics, it 
should be noted that a selection bias was introduced by only including data 
from patients with lesions proven by core or excision biopsy.
In summary, our findings suggest that CAD has the potential to improve the 
discrimination of benign from malignant breast lesions at 3T MRI. Additionally 
CAD may decrease the heterogeneity of radiologists of varying levels of 
experience in breast MR interpretation.
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Abstract
In a 55-year-old woman, an echographically occult breast tumor was only 
visible in one direction on mammography. MRI-guided needle localization 
of the lesion followed by surgical excision biopsy were then carried out for 
diagnostic purposes. In a second woman, 61 years of age, mammographic 
needle localization of a deep, echographically occult, lesion was unsuccessful. 
She then also underwent MRI-guided needle localization followed by surgical 
excision biopsy. A third woman, also 61 years of age, with known carcinoma 
underwent an MRI staging study. This revealed a second, mammographically 
and echographically occult, lesion for which MRI-guided large-core needle 
biopsy was done. MRI of the breast has a high sensitivity for the detection of 
invasive breast carcinoma. MRI of the breast reveals suspicious lesions that 
cannot be seen on the conventional mammogram or by echography in 15-25% 
of the cases. In order to obtain tissue from these lesions for histopathology, 
MRI-guided biopsy techniques have been developed. The most commonly 
used methods are MRI-guided needle localization followed by surgical excision 
biopsy and MRI-guided large-core needle biopsy. The demand for MRI-guided 
breast interventions is growing because of the increasing use of MRI of the 
breast in clinical practice.
Samenvatting
Bij een vrouw van 55 jaar was een echografisch occulte mammatumor bij 
mammografie slechts in één richting zichtbaar. Bij haar werd voor de diagnostiek 
MRI-geleide draadlokalisatie van de tumor verricht gevolgd door chirurgische 
excisiebiopsie. Bij een tweede vrouw, van 61 jaar, mislukte mammografische 
draadlokalisatie van een diepe echografisch occulte afwijking. Ook zij onderging 
MRI-geleide draadlokalisatie met chirurgische excisiebiopsie. Een derde vrouw, 
van 61 jaar, met een bekend carcinoom onderging MRI-stadiëringsonderzoek. 
Daarbij werd een tweede, mammografisch en echografisch occulte afwijking 
gezien waarvoor een MRI-geleide dikkenaaldbiopsie plaatsvond. MRI van de 
borst heeft een hoge sensitiviteit voor het detecteren van een invasief carcinoom. 
Bij 15-25% van de patiënten worden verdachte afwijkingen gediagnosticeerd 
op de MRI-scan, die niet op het conventionele mammogram of met echografie 
te zien zijn. Om van deze afwijkingen toch weefsel te verkrijgen voor 
histopathologisch onderzoek, zijn MRI-geleide biopsietechnieken ontwikkeld. 
De meest gebruikte technieken zijn de MRI-geleide draadlokalisatie gevolgd 
door chirurgische excisiebiopsie en de MRI-geleide dikkenaaldbiopsie. Door 
de toenemende vraag vanuit de kliniek naar MRI-beeldvorming van de borst 
neemt de behoefte aan MRI-geleide mamma-interventies toe.
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MRI wordt als beeldvormende techniek in toenemende mate gebruikt voor 
analyse en detectie van tumoren in de borst [1]. De reden hiervoor is de 
hoge sensitiviteit van MRI ten opzichte van conventionele mammografie en 
echografie voor detectie van invasieve tumoren, die bijna 100% bedraagt [2,3]. 
De specificiteit van MRI van de borst is echter beperkt en varieert van 40-95%, 
afhankelijk van de patiëntenselectie en de methoden die worden gebruikt voor 
analyse van de MRI-beelden [4]. Mede hierdoor wordt MRI van de borst klinisch 
altijd gebruikt als aanvulling op het standaardmammogram, dat het onderzoek 
van eerste keus is en blijft voor borstkankerdiagnostiek.
Klinisch geaccepteerde indicaties voor MRI-onderzoek van de borst zijn 
momenteel het screenen van hoogrisicopatiënten, analyse van onduidelijke 
afwijkingen die gezien zijn op het conventionele mammogram of bij echografie, 
preoperatieve stadiëring van patiënten met een bekend mammacarcinoom, 
follow-up van patiënten na borstsparende therapie en evaluatie van respons 
op neoadjuvante chemotherapie [3, 5-10]. Door de hoge sensitiviteit kan MRI- 
onderzoek van de borst een suspecte afwijking detecteren in de borst die 
zowel klinisch als mammografisch en echografisch occult is. Bekend is dat bij 
15-25% van alle patiënten die een MRI-onderzoek van de borst ondergaan een 
dergelijke afwijking wordt gevonden. Vanwege de beperkte specificiteit van 
MRI-onderzoek van de borst is dan een MRI-geleide biopsie de enige manier 
om tot een definitieve diagnose van de afwijking te komen [11].
Doordat het gebruik van MRI voor borstonderzoek aanzienlijk is toegenomen, 
stijgt landelijk eveneens de vraag naar mogelijkheid tot MRI-geleide biopsie 
van suspecte MRI-afwijkingen. Er zijn verschillende methoden ontwikkeld om 
tot weefseldiagnostiek van deze afwijkingen te komen. De meest gebruikte 
zijn MRI-geleide draadlokalisatie, gevolgd door een chirurgische excisiebiopsie 
en MRI-geleide stereotactische percutane dikkenaaldbiopsie [12-18]. 
Voorwaarden voor het toepassen van deze MRI-geleide invasieve diagnostiek 
zijn de beschikbaarheid van een MRI-borstspoel die voor interventies geschikt 
is en van biopsie-instrumentarium dat geschikt is voor MRI.
In dit artikel beschrijven wij aan de hand van enkele casussen de verschillende 
biopsiemethoden en maken wij het belang van deze methoden voor de 
dagelijkse klinische praktijk duidelijk.
37
Chapter 3
Ziektegeschiedenissen
Patiënt A, een 55-jarige vrouw, was elders voor een MRI van de borst geweest. 
Op de scan werd een afwijking in het laterale bovenkwadrant rechts gezien. 
Deze afwijking werd niet bij echografie teruggevonden en op het mammogram 
was de afwijking maar in één richting zichtbaar. Patiënte werd naar onze kliniek 
verwezen om een MRI-geleide draadlokalisatie van de afwijking uit te voeren. 
Gezien de vraagstelling werd alleen de rechter borst met MRI onderzocht. In 
het laterale bovenkwadrant van de rechter mamma werd een ovale, goed 
afgrensbare afwijking met een afmeting van 12 x 10 mm gevonden (figuur 
1a en b), conform het eerste diagnostische MRI-onderzoek. Na toediening 
van intraveneus contrastmiddel toonde de afwijking een indifferent 
aankleuringsprofiel, dat gekenmerkt werd door aanvankelijk een snelle 
opname van het contrastmiddel en vervolgens een plateaufase. De afwijking 
werd geclassificeerd als een 'Breast imaging reporting and data system' (MRI- 
BI-RADS) III, dat wil zeggen 'onzeker benigne' [20]. Onder MRI-geleide werd er 
stereotactisch een draadlokalisatie verricht. De tip van de titanium lokalisatie 
draad werd precies door de afwijking geplaatst en de weerhaakjes werden 
ontplooid (zie Figuur 1c en d). Uit het vervolgens genomen chirurgische 
excisiebiopt bleek dat het ging om een benigne afwijking bestaande uit een 
intramammaire lymfeklier en adenose. Controle-MRI na 6 maanden bevestigde 
dat de afwijking verwijderd was.
Patiënt B, een 61-jarige vrouw met een belaste familieanamnese voor 
borstkanker, had bij mammografie een verdachte afwijking diep dorsaal in 
de rechter borst. Met echografie was deze afwijking niet terug te vinden. Er 
werd een lokalisatieprocedure onder mammografiegeleide uitgevoerd. Door 
de locatie van de afwijking, die vrijwel tegen de M. pectoralis major aan lag, 
mislukte deze lokalisatie. Er werd aanvullende diagnostische MRI verricht; daarbij 
werd in het laterale onderkwadrant van de rechter mamma een ovale, scherp 
afgrensbare afwijking met een afmeting van 10 x 7 mm gezien. De afwijking 
was diep gelokaliseerd in de rechter mamma, 1 mm vanaf de M. pectoralis 
(Figuur 2a en b). De afwijking had een verhoogde signaalintensiteit op de T2- 
gewogen opnamen. Morfologisch paste het beeld bij een benigne afwijking. 
Na toediening van intraveneus contrastmiddel was er echter randaankleuring 
zichtbaar en was het bijbehorende aankleuringsprofiel pathologisch, 
gekenmerkt door een snelle opname van het contrastmiddel gevolgd door een 
geleidelijk verdwijnen (uitwassing). Daarom werd de afwijking geclassificeerd 
als MRI-BI-RADS IV, dat wil zeggen 'verdacht voor maligniteit'. Er werd besloten 
om onder MRI-geleide een draadlokalisatie uitvoeren.
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Figuur 1 . Patiënt A: transversale T1-gewogen opname met vetsuppressie toont na toediening 
van contrast een ovale, goed afgrensbare aankleurende laesie in het laterale bovenkwadrant 
van de rechter mamma (a). Deze laesie wordt teruggevonden op de T1 gewogen opname zonder 
contrastmiddel (b). De tip van de naald wordt precies voor de laesie geplaatst (c) en de draad 
wordt ingebracht. Bij een controle opname na het terugschuiven van de naald over de draad is 
te zien dat draad centraal door de laesie heen gaat (d).
Door de locatie van deze afwijking, dichtbij de thoraxwand, werd er gekozen 
voor de zogenaamde 'vrijehand'-methode (zie verderop) om de afwijking 
te benaderen (zie figuur 2c). Na de chirurgische excisiebiopsie bleek het bij 
histopathologisch onderzoek te gaan om een adenocarcinoom met een 
diameter van 8 mm, die in toto was verwijderd.
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Figuur 2 . Patiënt B: de transversale T1-gewogen opname (a) en saggitale T1-gewogen opname 
met vetsuppressie na toediening van contrast tonen een ovale scherp begrensde laesie dicht bij 
de m. pectoralis dorsaal in de rechter mamma (b). Met de "vrije-hand” methode wordt de kortste 
weg gekozen. Bij patiënt B wordt een naald vanaf de laterale zijde naar de laesie gebracht en de 
draad ontplooid (c).
Patiënt C was een een 61-jarige vrouw bekend wegens een carcinoom lateraal 
en craniaal in de linker borst. Voordat besloten werd om een borstsparende 
operatie uit te voeren werd diagnostische MRI verricht voor preoperatieve 
stadiëring. Het MRI-onderzoek van de borst toonde de bekende afwijking in 
het laterale bovenkwadrant van de linker borst (Figuur 3a). Het ging om een 
stervormige afwijking van 12 x 13 mm met een pathologisch aankleuringsprofiel 
gekenmerkt door een snelle opname van contrast gevolgd door een geleidelijk 
verdwijnen, passend bij het bekende invasief carcinoom: stadium MRI-BI- 
RADS VI, dat wil zeggen 'aangetoonde maligniteit'. Op 3 cm afstand, caudaal 
van deze eerste afwijking, in het laterale onderkwadrant, werd een tweede 
stervormige ruimte-innemende afwijking gezien met een afmeting van 8 x
7 mm, die eveneens pathologisch aankleurde na toediening van intraveneus 
contrastmiddel (zie Figuur 3b). Deze afwijking werd geclassificeerd als MRI-BI- 
RADS IV, dat wil zeggen 'verdacht voor maligniteit. Deze afwijking was noch 
op het conventionele mammogram gezien, noch bij echografie. Ook bij 
gerichte echografie, na het MRI-onderzoek van de borst, werd de afwijking niet 
teruggevonden. Daarom werd besloten tot een MRI-geleide dikkenaaldbiopsie 
van de afwijking (zie Figuur3c). Bij histopathologisch onderzoek van het biopt 
werd een invasief ductaal carcinoom gezien, waarna het therapeutische beleid 
werd omgezet van mammasparende therapie naar gemodificeerde radicale 
mastectomie.
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Figuur 3. Patiënt C: transversale T1-gewogen opname met vetsuppressie toont na toediening 
van contrast een stervormig aankleurende laesie in het laterale bovenkwadrant van de linker 
borst passend bij het bekende invasieve carcinoom (a). Iets meer naar caudaal in het laterale 
onderkwadrant een tweede stervormige laesie verdacht voor maligniteit (b). MRI-geleide 
dikkenaald biopt van de tweede laesie met de tip van de geleider precies voor de laesie (c). Het 
nemen van de dikkenaald biopten gebeurt buiten de magneet.
Beschouwing
Wanneer bij MRI-onderzoek van de borst een verdachte afwijking wordt 
gevonden die niet zichtbaar is op het mammogram moet volgens de 
richtlijnen aansluitend gerichte echografie van dat gebied worden verricht 
[20]. Bekend uit de literatuur is dat door middel van echografie van de mamma 
in retrospect 25% van de verdachte afwijkingen wordt teruggevonden [9­
21]. Deze groep kan aanvullend onder echogeleide worden gebiopteerd. 
Echogeleide dikkenaaldbiopsie heeft immers de voorkeur boven MRI-geleide 
dikkenaaldbiopsie, omdat echogeleide biopsie snel en eenvoudig uitvoerbaar 
is, realtimebeeldvorming mogelijk maakt, gepaard gaat met minder kosten en 
beter door de patiënt verdragen wordt.
Toch is bij 15-25% van alle patiënten die een MRI-onderzoek van de borst 
ondergaan de afwijking alleen zichtbaar op MRI [20]. De enige manier om 
bij deze patiënten tot weefseldiagnostiek van de afwijking te komen is MRI- 
geleide biopsie [11]. MRI-geleide draadlokalisatie gevolgd door chirurgische 
excisiebiopsie is de betrouwbaarste methode voor weefselanalyse van een 
verdachte afwijking in de borst die alleen zichtbaar is bij MRI-onderzoek, 
met een sensitiviteit tussen 95-100% [12-14,22]. Er zijn twee verschillende 
MRI-geleide draadlokalisatietechnieken. De meest gehanteerde is de 
stereotactische methode en de tweede is de reeds genoemde vrijehand 
draadlokalisatietechniek.
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MRI-geleide stereotactische draadlokalisatie.
Bij de MRI-geleide stereotactische draadlokalisatietechniek wordt de patiënt 
standaard in buikligging op de mammaspoel gepositioneerd (figuur 4a) en 
vervolgens wordt de borst gefixeerd tussen twee kunststof compressieplaten, 
waarvan de buitenste voorzien is van een raster (zie Figuur 4b) [12,13]. Vanaf 
lateraal wordt vervolgens een stereotactisch biopsiesysteem gemonteerd 
dat bestaat uit een staafje dat in de richting van de x-as te verschuiven is 
en daarop gemonteerd een holle geleider die in de richting van de y-as vrij 
instelbaar is. Onder MRI-beeldvorming (T1-gewogen opnamen) is het mogelijk 
om de lokalisatienaald vanaf lateraal, door de holle geleider, na verdoving 
van de huid, in te brengen en stapsgewijs in de borst op te schuiven tot aan 
de tumor. Vervolgens wordt de positie van de tumor ten opzichte van de 
naald gecontroleerd door een serie T1-gewogen opnamen met intraveneus 
contrastmiddel te maken, waarna de titanium lokalisatiedraad wordt ingebracht 
en door de tumor wordt geschoven tot de punt net voorbij de tumor is 
gepositioneerd. Na plaatsing van de draad ondergaat de patiënt, bij voorkeur 
diezelfde dag, een chirurgische excisie van het borstklierweefsel rondom de tip 
van de draad.
Een nadeel van de stereotactische draadlokalisatietechniek is dat met de 
biopsiesystemen alleen een benadering vanaf lateraal mogelijk is en voor 
lokalisatie van afwijkingen mediaal in de borst een relatief lang traject door 
de borst moet worden afgelegd; daardoor is deze methode minder geschikt 
voor het lokaliseren van dergelijke afwijkingen [12]. Vandaar dat momenteel 
stereotactische biopsiesystemen worden ontwikkeld waarmee ook een 
benadering vanaf mediaal mogelijk is [13]. Verder is het met de meeste 
systemen niet mogelijk om de naald geanguleerd in te brengen, waardoor 
afwijkingen posterieur in de borst moeilijk te benaderen zijn.
Figuur 4. Bij MRI onderzoek van de borst wordt gebruik gemaakt van een speciale borstspoel (a). 
Een stereotactisch systeem (b) voor een MRI-geleide draadlokalisatie of MRI-geleide dikke naald 
biopsie kan aan de zijkant van de borstspoel geplaatst worden. De geleider van dit systeem, 
waar de naald doorheen gaat kan in x en y richting tot op de millimeter nauwkeurig verschoven 
worden.
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MRI-geleide vrijehand-draadlokalisatie.
Bij de tweede techniek wordt, nadat de patiënt standaard in buikligging op 
de mammaspoel gepositioneerd is, de lokalisatienaald met de vrijehand- 
techniek ingebracht in een niet-gefixeerde borst [14]. Bij deze procedure wordt 
de insteekopening van de naald aan de hand van de MRI-beelden bepaald en 
vervolgens gemarkeerd met een ringvormige gadoliniummarker op de huid 
(zie Figuur 5). De naald wordt vervolgens ingebracht zoals bij een CT- of een 
echogeleide punctie gebeurt. De positie van de naaldtip ten opzichte van de 
tumor is door middel van MRI-opnamen te bepalen en stapsgewijs kan de tip 
van de naald tot op de gewenste positie worden gebracht. Men dient hiervoor 
wel de patiënt telkens in en uit de scanner te schuiven.
Het grote voordeel van deze techniek ten opzichte van het stereotactische 
systeem is dat het mogelijk is om de naald te anguleren. Hierdoor zijn 
afwijkingen posterieur in de borst, prepectoraal en in de axillaire uitloper te 
lokaliseren [14-20]. Een nadeel van deze techniek is dat de borst niet gefixeerd 
is door compressieplaten. Bij patiënten met compact fibroglandulair weefsel 
kan het dan noodzakelijk zijn om het naaldtraject te corrigeren tijdens het 
inbrengen en het opvoeren van de naald, omdat het klierweefsel en de tumor 
zich ten opzichte van de tip van de naald onder de druk verplaatsen. Fixatie van 
de borst met de hand is dan vaak voldoende om dit effect te minimaliseren en 
de lokalisatienaald toch op zijn plaats vlak voor de tumor te positioneren.
Figuur5. Bij de "vrije-hand” methode wordt er een ringvormige gadolinium marker op de huid 
geplakt. Aan de hand van deze marker kan de positie van de laesie in de borst t.o.v. de marker 
worden bepaald.
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Kanttekeningen.
Bij de introductie van MRI-geleide draadlokalisatietechnieken in de klinische 
praktijk zijn ook kanttekeningen te plaatsen. Zo worden deze lokalisaties net 
als röntgengeleide draadlokalisaties uitgevoerd met de patiënt in buikligging, 
terwijl bij de chirurgische excisie de patiënt in rugligging geplaatst is. Als 
gevolg hiervan zal de anatomie van de borst tijdens de draadlokalisatie 
verschillen van die tijdens de chirurgische excisie. Voor het slagen van MRI- 
geleide draadlokalisaties is derhalve een goede samenwerking vereist tussen 
uitvoerend radioloog en chirurg, waarbij de radioloog aan de hand van beelden 
de chirurg duidelijk toont hoe de positie van de tip van de lokalisatienaald 
ten opzichte van de tumor in de borst is. Bekend is dat wanneer de tip van de 
lokalisatienaald binnen 10 mm van de afwijking geplaatst is, de resultaten van 
een MRI-geleide en die van röntgengeleide draadlokalisatie vergelijkbaar zijn, 
dat wil zeggen een sensitiviteit van 98-100% voor het vinden van de tumor in 
het operatiepreparaat. Plaatsing van de draad op > 1 cm vanaf de tumorrand 
resulteert in een toename met ongeveer 5% van het aantal fout-negatieve 
procedures. 17 Studies hebben aangetoond dat bij 12-55% van de MRI- 
geleide draadlokalisaties een maligniteit wordt gevonden, een percentage dat 
vergelijkbaar is met de opbrengst van röntgen- of echogeleide draadlokalisatie 
[ 11,12,14]. Een nadeel van de MRI-geleide ten opzichte van de röntgengeleide 
draadlokalisaties is dat het maken van een specimenopname, dat wil zeggen 
van een postoperatieve röntgenopname van het verwijderde mammaweefsel 
om te bepalen of de afwijking in toto verwijderd is, geen waarde heeft, omdat de 
tumor immers niet op het mammogram zichtbaar was. Bij een benigne uitslag 
van het excisiebiopt dient derhalve altijd na 6 maanden (als het weefsel tot rust 
is gekomen) controle-MRI van de borst te worden verricht om verwijdering van 
de afwijking te bevestigen.
Wanneer het gaat om een maligne afwijking in het chirurgische excisiebiopt 
is het van belang te bepalen of de afwijking in zijn totaliteit verwijderd is. 
Indien de resectievlakken immers niet tumorvrij zijn, dient een re-excisie 
plaats te vinden. Gepubliceerde studies tonen dat het percentage re-excisies 
na MRI-geleide draadlokalisatie overeenkomt met het percentage re-excisies 
na röntgengeleide draadlokalisatie en rond de 43 ligt [23, 24]. Het aantal 
studies waarin het percentage re-excisies is onderzocht na MRI-geleide 
draadlokalisaties is echter nog schaars.
MRI-geleide dikkenaaldbiopsie.
Gezien het invasieve karakter van de draadlokalisatietechnieken met vervolgens 
de chirurgische excisie, zijn er de laatste jaren technieken ontwikkeld die MRI-
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geleide dikkenaaldbiopsie mogelijk maken [13, 16-21]. Bij deze procedure, 
die vergelijkbaar is met de MRI-geleide stereotactische draadlokalisatie, 
wordt de patiënt in buikligging op de mammaspoel geplaatst en de borst 
gefixeerd tussen de twee compressieplaten. Na berekening van de juiste 
introductieplaats, wordt de holle kunststofgeleider gefixeerd op het staafje 
van het stereotactische systeem. Vervolgens is het mogelijk om, na plaatselijke 
verdoving van de huid, de introductienaald door de geleider heen vanaf 
lateraal in de borst in te brengen en op te voeren tot aan de tumor. Uiteindelijk 
wordt buiten de magneet door de introductienaald de biopsienaald (14G) 
geplaatst en worden de biopten genomen. Nadelen van deze methode zijn 
dat door metaalartefacten van de introductienaald op de MRI-beelden kleine 
afwijkingen, dat wil zeggen met een diameter < 5 mm, moeilijk zichtbaar zijn 
en daarom niet nauwkeurig te biopteren zijn [25]. Tevens is het niet mogelijk 
om in een gesloten magneet opnamen te maken met de biopsienaald in 
situ, waardoor niet bewezen kan worden dat de afwijking daadwerkelijk is 
gebiopteerd. Vandaar dat patiënten een half jaar na een MRI-geleide biopsie 
een controlescan dienen te krijgen [11, 26].
MRI-vacuümbiopsiesysteem.
Een recente ontwikkeling is een MRI-vacuümbiopsiesysteem waarmee het 
mogelijk is om meer weefsel door de introductienaald in één keer te verwijderen 
[27-29]. Studies die de waarde van deze techniek evalueren voor het MRI-geleid 
biopteren van afwijkingen in de borst zijn gestart.
Conclusie
Gezien de toenemende vraag vanuit de kliniek naar MRI-beeldvorming van 
de borst neemt de behoefte aan MRI-geleide mamma-interventies toe. De 
technieken die momenteel voorhanden zijn, zijn MRI-geleide draadlokalisatie 
gevolgd door chirurgische excisiebiopsie en de MRI-geleide dikkenaaldbiopsie. 
Tot op heden is het gebruik van de technieken nog niet wijdverbreid en alleen 
voorhanden in specialistische centra. Per patiënt zal de radioloog in nauw 
overleg met de chirurg moeten bepalen welke methode de voorkeur heeft, met 
inachtneming van het feit dat elke methode haar eigen tekortkomingen heeft. 
MRI-geleide biopsie van afwijkingen in de borst is een techniek in ontwikkeling 
en zal in de toekomst toenemend een rol spelen bij de invasieve diagnostiek 
van mammatumoren.
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Targeting difficult accessible breast le­
sions: MRI-guided needle localization 
using a freehand technique in a 3T
closed bore magnet.
Chapter4
Abstract
Purpose
To report the accuracy of magnetic resonance imaging (MRI)-guided needle 
localization for diagnosis of MRI detected suspicious breast lesions located in 
difficult accessible regions of the breast, using the freehand method in a 3T 
closed bore magnet.
Materials and methods
In five patients with five MRI-only breast lesions underwent MRI-guided needle 
localization for histopathologic evaluation of the lesions. All interventional 
procedures were performed in a 3T MRI system with the patient in prone 
position and by using a dedicated phased array breast coil. MRI-guided needle 
localizations were performed by using a freehand technique. In our study, 
the high-resolution scan allowed preprocedural localization of all lesions 
without use of contrast enhancement. In all cases contrast-enhanced MRI was 
performed after insertion of the wire to confirm the tip of the wire in direct 
contact with the enhancing lesion.
Results
Needle localizations were performed in five patients. Histopathologic evaluation 
of tissue after surgery excision biopsy revealed one lymph node, three invasive 
ductal carcinoma and one ductal carcinoma in situ. Lesion size varied from 6 to 
30 mm. Mean duration time was 25 min. No complications occurred during the 
intervention method. In the patient with the benign lesion control MRI of the 
breast after 6 months confirmed lesion removal.
Conclusions
MRI-guided needle localization by using a freehand technique in a 3T closed 
bore magnet is a safe and accurate method for diagnosis of difficult accessible 
breast lesions only visible on MRI.
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Introduction
Magnetic resonance imaging (MRI) of the breast has proven to be a valuable 
complement to the conventional techniques - mammography, sonography, 
and physical examination - for breast cancer detection, diagnosis, staging, 
and treatment follow-up [1]. It is a more sensitive method than conventional 
mammography or ultrasound for detection of invasive tumors with a sensitivity 
approaching 100%. However, the specificity of MRI of the breast is rather 
variable ranging from 40 to 95%, depending on patient selection and imaging 
techniques used [2-6].
When suspicious enhancing breast lesions are detected with MRI solely, MRI- 
guided biopsy techniques are used for accurate sampling of the lesions and 
for histopathologic analysis. MRI-guided tissue sampling of these "MRI-only 
lesions'; can be accomplished either by needle localization followed by surgical 
excision, by MRI-guided large-core needle biopsy, or vacuum biopsy [7].
Of all technique MRI-guided needle localization is still considered the gold 
standard for tissue sampling especially for small and difficult accessible breast 
lesions [8]. A variety of techniques for MRI-guided needle localization have 
been described in the literature, including stereotactic localization with patient 
in supine position, localization with the patient prone and breast compressed 
through perforated compression plates, and finally a freehand localization 
technique with the patient in prone position [9-17]. Studies assessing the value 
of stereotactic localization using a grid system reported difficulties in lesion 
accessibility, especially posterior localized lesions near the chest wall, in the 
retroareolar region and lesions located medial in the breast [10-12]. It is reported 
that lesions which can be inaccessible with standard grid or compression-plate 
techniques, can be localized with the freehand method [13].
The freehand technique has only been described in a few studies [13-15]. The 
freehand technique has several potential advantages, it is a simple technique 
that is comparable with freehand lesion localization under ultrasound or 
computed tomography (CT) guidance. Furthermore, the method allows needle 
placement with a freely chosen insertion angle, enabling localization of lesions 
throughout the breast, including those in the anterior in the retroareolar region, 
those deeply localized near the chest wall, and lesion localizations in patients 
with silicon implants [13]. So far all previous studies focused on the utility of the 
technique in an open MRI system.
The purpose of this feasibility study is to report our experience with MRI-guided 
needle localization of suspicious breast lesions located in difficult accessible 
regions of the breast, using the freehand technique in a 3T closed bore magnet.
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Materials and methods
Patients and lesion characteristics
Five women, median age 61 (56-64 years), with difficult accessible, MRI-only 
breast lesions were consecutive recruited and underwent closed bore 3.0 TMRI- 
guided needle localization by using the freehand technique in our hospital 
from June 2005 to March 2006. Indications for diagnostic breast MRI and the 
localization procedure were acquired from the patients' files. If the lesion was 
not visible on ultrasonography in retrospect, MRI guided needle localization 
was performed. In all benign cases a 6 months follow-up MRI was performed to 
confirm lesion removal.
Breast MRI: technique
MRI of the breast was performed in all patients after conventional mammography 
and ultrasonography. MRI was performed on a 3T clinical MR system (3T Achieva, 
Philips Medical Systems, Best, The Netherlands). Patients were placed in the 
prone position on a dedicated phased-array bilateral breast coil (MRI devices, 
Wurzburg, Germany) utilized for simultaneous imaging of both breasts (Figure
1). Transverse high-resolution T1weighted fast field echo (T1-FFE) images were 
obtained (TE/TR 1.7/4.5 ms; inversion delay SPAIR 130 ms; flip angle 10°; FOV 
340mmx340 mm, acquired voxel size 0.66mmx0.66mmx1.6 mm, reconstructed 
voxel size 0.66mmx0.66mmx0.80 mm), followed by transverse T2-weighted 
fat suppressed images (TE/TR 120/9022 ms; inversion delay SPAIR 125 ms; flip 
angle 90°; FOV 340mmx340 mm, Figure 1. Patients were placed in the prone 
position on a dedicated phased-array bilateral breast coil. Acquired voxel size 
1.01mmx1.31mmx2.0 mm, reconstructed voxel size 0.66mmx0.66mmx2.00 
mm). Finally, dynamic contrast-enhanced fat-suppressed T1-weighted images 
(TE/TR 1.3/3.4 ms; flip angle 10°; FOV 320mmx320 mm, acquired voxel size 
0.91mmx0.91mmx2.00 mm, reconstructed voxel size 0.83mmx0.83mmx1.00 
mm; dynamic scan duration 60 s), started after intravenous bolus injection of
0.1 mmol/kg Magnevist, Schering, Germany) were acquired.
52
Targeting difficult accessible breast lesions
Figure 1. Patients were placed in the prone position on a dedicated phased-array bilateral breast 
coil.
Interpretation of breast MRI
Breast MR images were interpreted on workstation using a picture archiving 
and communications system (PACS, Philips, Best, The Netherlands). The breast 
images were interpreted in conjunction with other breast images, including 
mammograms and sonograms when available.
Level of suspicion was reported on a scale of 0-6, identical to that in the lesion­
assessment categories used in the breast imaging reporting and data system (BI­
RADS) [18]. Numeric categories were the following: 0, needs additional imaging 
evaluation; 1, normal; 2, benign; 3, probably benign, recommend 6-month 
follow-up MRI; 4, suspicious; 5, highly suggestive of malignancy; 6 proven 
malignancy. Classification was based on lesion morphology and enhancement 
kinetics [17-19]. For lesions interpreted as suspicious or highly suggestive of 
malignancy on MRI, correlative sonography was often performed to determine 
if the lesion was ultrasonographically evident and, thereby amenable to tissue 
sampling under ultrasonographic guidance.
MRI-guided needle localization: technique
The localization was performed with the patient positioned prone with 
both breasts in a dedicated surface breast coil. All needle localizations were 
performed by using a freehand technique, as first described by Daniel et al. [13].
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This technique started by fixing a fiducial marker doped with gadolinium to 
the skin of the breast overlying the approximate position of the lesion (Figure 
2). The coordinates of the fiducial marker were taken from an axial image. To 
visualize the lesion we used the same T1-FFE technique as the diagnostic breast 
MRI. In our study, all lesions could be identified as low signal intensity mass, 
as defined by the MRI BI-RADS lexicon, on the high resolution pre-contrast T1 
weighted images. To determine the optimal needle entry site on the skin, the 
marker was repositioned and re-imaged until both the center of the fiducial 
marker and the center of the suspected target were visualized in the same axial 
image. After correct position of the fiducial marker, the patient was moved out 
of the magnet and the skin entry was marked with a pen. The patient's skin 
was sterilized, and superficial, sub-dermal anaesthetic (lidocaine 1%) 10 ml was 
injected superficial. A titanium MRI-compatible 18G needle (Somatex Medical 
Technologies GmbH Germany) was inserted into the marked skin entry site and 
directed along the planned needle approach. The MRI table was returned to 
the bore of the magnet and an axial sequence with contrast-enhancement was 
obtained through the region of the needle and the lesion to confirm accurate 
placement of the needle. After correct placement of the needle was confirmed, 
the MRI table was rolled out of the magnet and an MRI compatible hook wire 
was deployed. Diagnostic contrast-enhanced breast imaging was performed 
after insertion of the wire to confirm the tip of the hook wire in direct contact 
with the enhancing lesion and to document the final trajectory of the hook 
wire (Figure 3). The patient was then transferred to surgery and excision at the 
localized site was performed using a wide excision to ensure removal of the 
suspect area.
Figure2 . A fiducialmarker doped with gadolinium is fixed to the skin of the breast.
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Figure 3. Patient B, a 61-year-old female patient, diagnosed with an oval mass with irregular 
margins on the axial T1-FFE image, localized deeply near the chest wall (a). Sagittal, contrast- 
enhanced, fat-suppressed T1-weighted image shows the lesions with rim enhancement (b). This 
lesion was successfully localized with the freehand technique (c).
Results
In five patients MRI-guided needle localization by using the freehand technique 
was performed (Table 1). All patients had a diagnostic MRI performed prior to 
the date of biopsy at our clinic; one had MRI performed for high risk screening, 
because there was a history of cancer and two for problem solving (one included 
analysis questionable breast lesions at conventional imaging modalities and 
the other had nipple discharge with an unknown primary). The remaining 
two patients underwent MRI of the breast because of pre-operative staging. 
Lesion size varied from 6 to 30 mm. The location of the lesions on MRI was: the 
upper outer quadrant, the lower outer quadrant, 1mm of the pectoralis muscle, 
the upper outer quadrant near the axillary tail and the anterior part of the 
breast near nipple. None of these suspicious lesions could be sonographically 
identified.
In all patients the tip of the wire was placed within 1 cm of the edge of the 
lesion (Table 2). Histopathologic evaluation of tissue after surgery excision 
biopsy revealed one lymph node, two invasive ductal carcinomas, one high 
grade ductal carcinoma in situ, and one mucinous carcinoma. Mean duration 
time was 25 min. No complications occurred during the intervention method. 
In the patient with the benign lesion (patient A) a control MRI of the breast after 
6 months confirmed lesion removal.
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Table 1. Patient and lesion characteristics
Patient Age Indication for MRI Lesion size (mm) Localization lesion BI-RADS
A 56 Problem solving 12 x 10 Posterior, 7 mm Pectoralis 4
B 61 Preoperative staging 10 x 7 Prepectoral, 1 mm of the 
pectoralis
4
C 64 High risk screening 8 Very posterior, 6 mm of the 
pectoralis
3
D 61 Problem solving 30 Anterior, 12 mm of the nipple 3
E 63 Preoperative staging 6 Posterior, 8 mm of the pectoralis 6*
* This patient diagnosed with invasive ductal carcinoma after large-core needle biopsy. Mammo- 
graphic needle localization followed by surgical excision was performed, but no malignancy was 
found on pathology. Because scar tissue after surgery obscured the lesion on mammography, 
MRI-guided needle localization followed.
Table 2 . Histopathologic findings after needle localization in each patient
Patient Distance between needle tip and 
lesion
Histopathologic findings Size lesion
(mm)
A Tip threw lesion Lymph node 10 x 11
B 2 mm (medial) and 2 mm (anterior) Invasive ductal carcinoma with 
intermediate grade ductal 
carcinoma in situ
8
C 5 mm (ventral) Invasive ductal carcinoma 9
D Tip threw lesion High grade ductal carcinoma in situ 34
E Tip threw lesion Invasive ductal carcinoma 7
Discussion
In this paper, we presented the results of MRI-guided needle localization of 
suspicious breast lesions by using a freehand technique on a 3T closed bore 
magnet. In total, we successfully performed MRI-guided needle localizations 
of difficult accessible breast lesions in five patients. Although ours was a small 
series, the findings suggest that this localization technique is feasible, fast and 
accurate (100%) in a closed bore magnet.
The primary method for sampling MRI-detected lesions remains the 
stereotactic localization with the grid technique. With this technique, the breast 
is compressed in the sagittal plane between two plates. A compression plate 
perforated by narrow-spaced holes (grid) allows horizontal needle insertion in 
the breast. Systems that use a grid proved to have several limitations [9, 10]. 
Any arrangement of holes will limit the access to areas that are located between 
the holes. This may be of special importance in small lesions. Another problem
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is localizing lesions in the retroareolar region because this part of the anterior 
breast cannot be adequately stabilized. Lesions near the chest wall and in the 
axillary tail, as in our study can also be difficult to localize by using a grid.
In contrast to this technique, the freehand method allowed needle placement 
with a freely chosen insertion angle, enabling localization of lesions throughout 
the breast, from near the chest wall to lesions superficially located near 
the nipple. Another advantage of not using a grid is that the breast is not 
compressed between the compression plates. Variation of the target lesion 
between the diagnostic MRI and the images obtained during localization will 
not occur and also contrast material enhancement will not be reduced due to 
the breast compression.
Recent developed stereotactic systems allow both lateral and medial breast 
access, however, most of (the older) stereotactic systems in use only allow lateral 
approach to the breast with horizontal needle insertion. Needle localization 
of lesions located medial in the breast causing longer tissue penetration and 
suboptimal localization. With the freehand method any approach (including a 
medial approach) can be established.
Freehand localization can be done in the supine or prone position. In the 
supine position the breast is taped against the chest wall to reduce shift. In this 
position there is a free access to the skin surface and the needle can be passed 
perpendicular to the skin surface in a similar manner to CT guided biopsy. 
Disadvantages of the supine method are problems in identification of the 
lesion due to different breast configuration compared to prone position of the 
pre-procedural diagnostic MRI, motion artifacts and limited resolution of the 
breast by not using a dedicated breast coil. Based on these disadvantages we 
performed the freehand localization procedure in the patient prone position. 
Breast motion did not occur in our experience, because of the weight of the 
patient's prone body fixes the chest wall to the coil platform. According to 
Coulthard, a limitation of freehand localization in the prone position with the 
breast in a dedicated breast coil limits needle access [20]. In our study, we had 
no problems localizing the target lesion with the breast in a dedicated breast 
coil, due to the tangential needle placement.
Several authors reported that freehand localization of a breast lesion also could 
be performed under CT guidance [9, 21]. This technique has a similar accuracy, 
however, a disadvantage is the re-identification of the lesion due to differences 
in the contrast enhancement and architecture of the breast between MR and 
CT. CT-guided percutaneous biopsy is not recommended for the same reason 
as the MRI-guided freehand technique in the patient supine position [21].
Most radiologists in practice as in our clinic operate in a closed bore magnet. 
Open magnets are not as widely available and are in general not used for breast
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imaging for reasons of limited image quality. A great advantage of these open 
magnets is the possibility of needle localization procedures without the need 
to move the patient in and outside the magnet. Daniel et al. showed excellent 
results by using an open bore magnet with real-time imaging [13]. In our 
study, direct monitoring of the procedure was not possible, but all the lesions 
were localized fast and accurately. In all cases contrast-enhanced MR imaging 
confirmed correct positioning of the wire through the target lesion, and no 
contrast suffusion after needle biopsy occurred.
The result of our feasibility study showing 100% accuracy is in accordance with 
the results of previous studies on MRI-guided stereotactic needle localizations, 
reporting technical success rates ranging from 96 to 100% [2, 7, 17, 24-26]. 
The success rate of mammographic-guided needle localization is 92-100% 
[27-29]. According to these results we can hypothesize that if mammographic 
localization procedure fails, MRI-guided needle localization is a good alternative 
to allow preoperative marking, when the lesion is not seen on sonography. 
Using the freehand method could be used when the cause of this failure is due 
to the localization of the lesion near the chest wall or the axillary tail.
A "second look" sonography is frequently attempted to identify suspicious 
lesions found on MR imaging, however only 25% of MRI-detected suspected 
breast lesions is sonographically visible in retrospect. Furthermore, even when 
a ultrasonographic abnormality is detected, MRI-guided tissue sampling 
may still be preferred since it may be impossible to prove that the purported 
sonographic lesions is the same as the MRI lesion [22,23].
Because of a lack of contrast-enhanced specimen MRI techniques after the MRI- 
guided needle localization and surgical biopsy there is no direct verification 
that the correct area has been excised. Placement of an MRI-compatible and 
mammographically visible clip that can be left behind after needle localization 
may support lesion identification. Post-operative follow-up MRI can also be 
used to document successful lesion excision. Another problem is that MR 
imaging may be difficult for the surgeon during excision and for the pathologist 
in the specimen.
To anaesthetize the skin of the breast we injected superficial, sub-dermal 
anaesthesia, before we inserted an 18G needle into the breast. Deep anaesthesia, 
in case of MRI-guided large core needle biopsy may cause blurring of the target 
lesion. This phenomenon is caused by the T1 lengthening of lidocaine fluid 
resulting in low signal intensity fluid that may obscure the low signal intensity 
target lesion. If MRI-guided needle localization will be performed, superficial 
anaesthesia can be provided to avoid blurring.
Imaging at 3T with a dedicated breast coil offers several advantages, which may 
allow for more accurate localization of the breast lesion on the non-contrast
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image, due to the achievable high spatial resolution. In our study, all the lesions 
could be identified without contrast material enhancement. This allows proper 
identification of the target lesion during the localization procedure on the non­
enhanced T1 FEE-weighted images by using the breast architecture as map. 
After the procedure the needle position is checked with contrast-enhanced 
images.
The results of this feasibility study show that freehand MRI-guided needle 
localization in a 3T closed bore magnet is technically feasible and safe. In all 
patients it allowed accurate tissue sampling of the lesion (100%). An advantage 
of the freehand technique compared to techniques that use a grid, is the ability 
to localize lesions throughout the breast. Larger studies will be needed before 
the freehand technique can be accepted in routine clinical practice for MRI- 
guided localization of difficult accessible breast lesions.
59
Chapter 4
References
1. Orel SG, Schnall MD, LiVolsi VA, et al. (1994) Suspicious breast lesions: MR imaging with 
radiologic-pathologic correlation. Radiology 1994;190:485-93.
2. Daniel BL, Yen YF, Glover GH, et al. (1998) Breast disease: dynamic spiral MR imaging. Radiology 
209:499-509.
3. Harms SE, Flamig DP, Hesley KL, et al. (1993) MR imaging of the breast with rotating delivery of 
excitation off resonance: clinical experience with pathologic correlation. Radiology 187 May 
2:493-501.
4. Boetes C, Barentsz JO, Mus RD, et al. (1994) MR characterization of suspicious breast lesions 
with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 193(December 
(3)):777-81.
5. Stomper PC, Herman S, Klippenstein DL, et al. (1995) Suspect breast lesions: findings at dynamic 
gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. 
Radiology 197(November (2)):387-95.
6. Bone B, Aspelin P, Bronge L, Isberg B, Perbeck L, Veress B (1996) Sensitivity and specificity of 
MR mammography with histopathological correlation in 250 breasts. Acta Radiol 37(March 
(2)):208-13.
7. Kuhl CK, Elevelt A, Leutner CC, Gieseke J, Pakos E, Schild HH (1997) Interventional breast MR 
imaging: clinical use of a stereotactic localization and biopsy device. Radiology 204:667-75.
8. van den Bosch MA, Daniel BL (2005) MR-guided interventions of the breast. Magn Reson 
Imaging Clin N Am 13(August (3)):505-17.
9. Heywang-Kobrunner SH, Heinig A, Pickuth D, Alberich T, Spielmann R (2000) Interventional MRI 
of the breast: lesion localization and biopsy. Eur Radiol 10:36-45.
10. Orel SG, Schnall MD, Newman RW, Powell CM, Torosian MH, Rosato EF (1994) MR imaging 
guided localization and biopsy of breast lesions: initial experience. Radiology 193:97-102.
11. Lampe D, Hefler L, Alberich T, et al. (2002)The clinical value of preoperative wire localization of 
breast lesions by magnetic resonance imaging—a multicenter study. Breast Cancer Res Treat 
75:175-9.
12. Morris EA, Liberman L, Dershaw DD, et al. (2002) Preoperative MR imaging guided needle 
localization of breast lesions. AJR 178:1211-20.
13. Daniel BL, Birdwell RL, Ikeda DM, et al. (1998) Breast lesion localization: a freehand, interactive 
MR imaging-guided technique. Radiology 207:455-63.
14. Brenner RJ, Shellock FG, Rothman BJ, Giuliano A (1995) Magnetic resonance imaging— guided 
preoperative breast localization using "freehand technique". Br J Radiol 68:1095-8.
15. Lee CH, Smith RC, Levine JA, et al. (1999) Clinical usefulness of MR imaging of the breast in the 
evaluation of the problematic mammogram. AJR 173:1323-9.
16. Friedman P, Sanders L, Russo J, et al. (2005) Detection and localization of occult lesions using 
breast magnetic resonance imaging: initial experience in a community hospital. Acad Radiol 
12(June (6)):728-38.
17. Veltman J, Boetes C, Wobbes T, et al. (2005) Magnetic resonance-guided biopsies and 
localizations of the breast: initial experiences using an open breast coil and compatible 
intervention device. Invest Radiol 40(June(6)):379-84.
60
Targeting difficult accessible breast lesions
18. Ikeda DM, Hylton NM, Kinkel K, et al. (2001) Development, standardization, and testing of a 
lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn 
Reson Imaging 13:889-95
19. Kuhl CK (2000) MRI of breast tumors. Eur Radiol 10:46-58.
20. Coulthard A (1996) Magnetic resonance imaging-guided pre-operative breast localization 
using a "freehand technique". Br J Radiol 69(May (821)):482-3.
21. Viehweg P, Heinig A, Amaya B, et al. (2002) MR-guided interventional breast procedures 
considering vacuum biopsy in particular. Eur J Radiol 42:32-9.
22. Brenner RJ, Rothman BJ (1997) Detection of primary breast cancer in women with known 
adenocarcinoma metastatic to the axilla: use of MRI after negative clinical and mammographic 
examination. J Magn Reson Imaging 7(November-December (6)):1153-8.
23. Steunebrink M, Schnater JM, Storm RK, van Ingen G, Vegt PA, Plaisier PW (2005) Bilateral axillary 
metastases of occult breast carcinoma: reportof a case with a review of the literature. Breast 
14(April (2)): 165-8.
24. Fischer U, Kopka L, Grabbe E (1998) Magnetic resonance guided localization and biopsy of 
suspicious breast lesions. Top Magn Reson Imaging 1998;9:44-59.
25. Pfleiderer SO, Reichenbach JR, Azhari T, Marx C, Wurdinger S, Kaiser WA (2001) Dedicated 
double breast coil for magnetic resonance mammography imaging, biopsy, and preoperative 
localization. Am J Surg 182(December (6)):584-9; Pfleiderer SO, Reichenbach JR, Azhari T, 
Marx C, Wurdinger S, Kaiser WA (2003) Dedicated double breast coil for magnetic resonance 
mammography imaging, biopsy, and preoperative localization. Invest Radiol 38(January (1)):1-8.
26. Smith LF, Henry-Tillman R, Rubio IT, Korourian S, Klimberg VS (2001) Intraoperative localization 
after stereotactic breast biopsy without a needle. Am J Surg 182(December (6)):584-9.
27. Jackman RJ, Marzoni Jr FA (1997) Needle-localized breast biopsy: why do we fail? Radiology 
204(September (3)):677-84.
28. Abrahamson PE, Dunlap LA, Amamoo MA, Schell MJ, Braeuning MP, Pisano ED (2003) Factors 
predicting successful needle-localized breast biopsy. Acad Radiol 10(June (6)):601-6.
29. Riedl CC, Pfarl G, Memarsadeghi M, et al. (2005). Lesion miss rates and false-negative rates for 
1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with 
long-term follow-up. Radiology 237(December (3)):847-53.
61
Peters NH, Meeuwis C, Bakker CJ, Mali WP, Fernandez-Gallardo AM, 
van Hillegersberg R, Schipper ME, van den Bosch MA.
Eur Radiol. 2009 Feb 13.
Chapter 5
'T fc v v .1 v.
& 4
0K%
Feasibility of MRI-guided large- 
core-needle biopsy of suspicious
breast lesions at 3 T
f l
Chapter5
Abstract
The feasibility of large-core-needle magnetic resonance imaging (MRI)-guided 
breast biopsy at 3T was assessed. Thirty-one suspicious breast lesions shown 
only by MRI were detected in 30 patients. Biopsy procedures were performed in 
a closed-bore 3T clinical MR system on a dedicated phased-array breast coil with 
a commercially available add-on stereotactic biopsy device. Tissue sampling 
was technically successful in 29/31 (94%) lesions. Median lesion size (n = 29) 
was 9 mm. Histopathological analysis showed 19 benign lesions (66%) and one 
inconclusive biopsy result (3%). At follow-up of these lesions, 15 lesions showed 
no malignancy, no information was available in three patients and two lesions 
turned out to be malignant (one lesion at surgical excision 1 month after biopsy 
and one lesion at a second biopsy because of a more malignant enhancement 
curve at 12-months follow-up MRI). Nine biopsy results showed a malignant 
lesion (31%) which were all surgically removed. No complications occurred. MRI- 
guided biopsy at 3 T is a safe and effective method for breast biopsy in lesions 
that are occult on mammography and ultrasound. Follow-up MRI at 6 months 
after the biopsy should be performed in case of a benign biopsy result.
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Introduction
Magnetic resonance imaging (MRI) of the breast is a promising diagnostic 
technique with a high sensitivity and a reasonable specificity for the detection 
of invasive breast tumors [1,2]. Approximately 10% of patients with a malignant 
breast lesion detected on mammography has an additional malignancy that is 
mammographically and ultrasonographically occult [3,4].When these additional 
suspicious breast lesions are detected on MR images, histopathological analysis 
is required. MRI-guided tissue sampling of these "MRI-only lesions" can be 
accomplished by means of wire localization and surgical excision, vacuum- 
assisted biopsy, or by large-core-needle biopsy (LCNB) [5].
LCNB has several advantages over wire localization, including decreased 
invasiveness, morbidity, and costs [6,7]. MRI-guided breast biopsy performed 
at 1.5T, using a 14G MRI-compatible needle, has been reported to have 98% 
diagnostic accuracy [8]. Some authors do not recommend MRI-guided core 
biopsy for lesions <10 mm, because the results are often inconclusive [6,9]. 
Nevertheless, the demand for biopsy of suspect sub-centimeter MRI-only 
lesions is high.
MRI systems operating at high magnetic fields strengths (e.g., 3T) become 
increasingly available in the clinical setting. The possibility of acquiring high­
resolution images in a short period of time, nominates 3-T breast imaging as a 
promising alternative to 1.5T imaging for diagnostic purposes. The possibility 
of decreasing MR data acquisition time while retaining an acceptable signal- 
to-noise ratio (SNR) and spatial resolution makes high-field MRI appealing 
for interventional purposes as well. However, if breast biopsies were to be 
performed at 3T, the susceptibility artifact of the needle would become larger 
and could complicate accurate tissue sampling. This prompted us to assess the 
feasibility of 3T MRI-guided LCNB of suspicious nonpalpable breast lesions.
Materials and methods
Patient characteristics
Thirty-one women (mean age: 48 years; range: 29-78) with 32 suspicious breast 
lesions which were only detected by MRI (MRI-only) were examined between 
September 2005 and February 2008. Indications for diagnostic breast MRI were 
problem solving (n = 11), increased risk of breast cancer (n = 7), preoperative 
staging (n = 3), work-up of a nonpalpable breast lesion (n = 5), tumor­
positive axillary lymph node with negative mammography (n = 1), bloody 
nipple discharge (n = 2) and unknown (n = 2). Patients were referred for MRI-
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guided biopsy from ten different hospitals. Of the 32 lesions, 18 lesions were 
characterized as BI-RADS-MRI III, nine lesions as BI-RADS-MRI IV and four as a BI- 
RADS-MRI V lesion. The BI-RADS-MRI classification of one lesion was unknown. 
No approval by the ethics board or informed consent was obtained because the 
MRI-guided breast biopsies were not performed in a study setting, but in the 
clinical setting. In our country, patients do not have to give informed consent 
for a clinical procedure.
MRI-guided biopsy procedure and equipment
Second-look ultrasound was recommended in all patients; if the lesion could 
be retrieved on ultrasound images, ultrasound-guided biopsy was performed; 
if the lesion was occult on ultrasound images, MRI-guided biopsy was 
performed. MRI-guided biopsies were performed on a 3T clinical MR system 
(Achieva, Philips Healthcare, Best, The Netherlands). Patients were placed in 
the prone position in a dedicated phased-array bilateral breast coil, with the 
affected breast in a dedicated breast coil which had an add-on biopsy device 
with a medial and lateral compression plate (Figure 1) (MRI Devices, Würzburg, 
Germany). The biopsy system comprised a gadolinium-filled guiding marker 
tube that can be positioned in the feet-head and anterior-posterior direction 
along a centimeter scale and angulated around the feet-head axis from +45° to 
-45° degrees. First, fat-suppressed high-resolution Tl-weighted gradient-echo 
images were acquired after the administration of 0.1 mmol/kg gadolinium 
(Magnevist, Bayer-Schering, Germany) to verify the position of the lesion. The 
administration of the contrast agent was delayed as long as possible during 
the procedure to avoid vanishing of the target lesion. The main parameters of 
this MR sequence are listed in Table 1. After correct positioning of the marker 
tube, the table top was moved out of the bore and local anesthesia (lidocaine 
1%) was administered subcutaneously. The marker tube was replaced by a 14G 
sterile biopsy needle surrounded by a 13G needle holder (Somatex, Teltow, 
Germany). The needle and sheath were horizontally inserted in the breast 
and advanced towards the lesion. The position of the needle and sheath were 
confirmed by using the fat-suppressed high-resolution T1-weighted gradient­
echo sequence. After correct placement of the biopsy needle was confirmed, 
the 14G biopsy gun (Somatex, Teltow, Germany) was inserted through the 
sheath and three to five tissue samples were obtained.
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Figure 1. Stereotactic system for MRI-guided preoperative wire-localization and breast biopsy. 
This system consists of a breast coil, which can be used for diagnostic MRI of the breast, and an 
add-on stereotactic device. The breast is compressed by two compression plates. The system 
allows angulation of the needle.
Table 1. Main scan parameters of the fat-suppressed high-resolution T1-weighted gradient-echo 
sequence used for guiding the biopsy procedure
Biopsy protocol
TE/TR (ms) 1.7/4.5
Flip angle 10°
Fat suppression Waterselective excitation pulse (PROSET)
Field of view (mm2) 340x 340
Matrix 256x 320
Read-out bandwidth (Hz) 1,443
Direction read-out gradient Perpendicular to B0
Effective slice thickness (mm) 2
Number of slices 75
Acquired voxel size (mm3) 1.09 x 1.09 x 2.00
Reconstructed voxel size (mm3) 1.09 x 1.09 x 1.00
Fast imaging Scan percentage 80%, over contiguous slices
Scan duration (min) 1.24
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Data collection
Histopathological analysis of the lesions was performed and lesions were 
classified in two categories: benign or malignant. In case of a benign lesion, 
the images of the biopsy procedure were re-evaluated to determine whether 
the tissue samples were representative. If the samples were considered not 
representative, a second biopsy or surgical excision was performed, based on 
the level of suspicion of malignancy and patient preference. Malignant lesions 
were surgically removed.
Results
Of the 32 suspicious MRI-only lesions, one lesion was seen on second-look 
ultrasound, and was therefore sampled under ultrasound guidance. In all other 
cases, MRI-guided biopsy was performed. In two cases, MRI-guided biopsy was 
not feasible: in one patient a 9-mm lesion was located directly posterior to the 
mammilla and in another patient a 9-mm lesion was located directly anterior 
to the thoracic wall (Fig. 2). No adequate compression could be achieved in the 
region in which the lesions were located, which made introduction of the biopsy 
needle not feasible in both cases. In the other 28 patients with 29 lesions, the 
3T MRI-guided LCNB was considered to be technically successful. The size of the 
needle artifact was 9.5 mm. A typical example of the acquired images during 
the procedure is shown in Fig. 3. None of the procedures had to be interrupted 
or stopped. No severe side effects were observed.
Figure 2 . a, b Two lesions in which MRI-guided biopsy was not feasible. a A 9-mm lesion located 
directly posterior to the mammilla. b A 9-mm lesion located directly anterior to the thoracic 
wall. In both cases the part of the breast which contained the lesions could not be adequately 
compressed.
68
Feasibility of MRI-guided large-core-needle biopsy of suspicious breast lesions at 3 T
Figure 3. a-c Typical example of a biopsy procedure. a Diagnostic post-contrast T1-weighted 
image shows suspicious lesion. b Pre-biopsy image, compressed breast with guiding marker 
tube at the same location as the lesion. c The needle is inserted in front of the lesion; 3-5 samples 
were obtained. Histology: DCIS
The 'MRI-only' lesion size ranged from 3 to 45 mm with a median lesion size 
of 9 mm. Histopathological analysis of the biopsy samples resulted in 19/29 
(66%) benign lesions (two fibroadenomas, three fibrocystic changes, six 
hyperplasias/adenoses, five normal fibroglandular tissues, one intramammary 
lymph node, one lobular carcinoma in situ (LCIS) and one papilloma) (Table 2). 
The results of one biopsy procedure were inconclusive (1/29, 3%). This lesion 
was surgically removed, histopathological analysis showed no malignancy. 
Follow-up was heterogeneous (Figure 4) due to large number of referring 
hospitals. In summary, follow-up of the 20 non-malignant biopsies showed no 
malignancy in 15 cases and revealed two malignant lesions: one LCIS lesion was 
surgically removed 1 month after the biopsy and additional ductal carcinoma 
in situ (DCIS) and a small invasive ductal component were demonstrated 
during pathological analysis of the lump. The second case showed a more 
malignant kinetic enhancement curve at 12-months follow-up MRI. The lesions 
was sampled again and pathology showed an invasive lobular carcinoma. No 
follow-up information was available in three patients.
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Figure 4. Flow chart of MRI-guided biopsy lesions and follow-up
Table 2 . Histological results of the lesions, lesion size and details on the problem cases (FCC 
fibrocystic change, LCIS lobular carcinoma in situ, DCIS ductal carcinoma in situ, ILC invasive 
lobular carcinoma, IDC invasive ductal carcinoma)
Number of lesions Size (mm)
Benign 19 Median: 8 mm
- Fibroadenoma 2 11, 20
- FCC 3 8, 12, 45
- Adenosis/hyperplasia 6 3, 6, 7, 9, 10, 15
- Normal breast tissue 5 5, 6, 7, 7, 8
- Lymph node 1 7 At 12-month follow-up MRI: more 
malignant enhancement curve; 
second biopsy showed ILC
- LCIS 1 8 At surgery LCIS, DCIS and small 
invasive ductal component 
(3-4 mm)
- Papilloma 1 30
- Non-representative 1 10 FCC at surgery
Malignant 9 Median: 11 mm
- DCIS 2 18, 35
- ILC 2 6, 7
- IDC 2 8, 26
- Adenocarcinoma 3 6, 11, 30
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Nine lesions (9/29, 31%) showed malignant pathological features in the sampled 
tissue: two ductal carcinomas in situ, two invasive lobular carcinomas (apart 
from the lesion described above), two invasive ductal carcinomas and three 
adenocarcinomas (Table 2). All malignant lesions were surgically removed: 
modified radical mastectomy (n = 3), breast conserving surgery (n = 3), unknown 
type of surgery (n = 3).
Discussion
We report our preliminary experience in MRI-guided large-core-needle breast 
biopsies using a 3T closed-bore clinical MRI system. In our patient series, MRI- 
guided LCNB was technically successful in 94% of patients (29/31). Two lesions 
could not be sampled since both lesions were located in a difficultly accessible 
location in the breast. In the most proximal and the most distal parts of the 
breast, adequate compression is difficult to achieve, which makes introduction 
of the biopsy needle not feasible. We advise to pursue MRI-guided breast 
biopsies even in these areas of the breast. If tissue sampling turns out not to be 
feasible, follow-up MRI is advised (to assess growth or change in the dynamic 
enhancement curve) or surgical excision of the lesions depending on the level of 
suspicion of malignancy. To increase the diagnostic accuracy of tissue sampling 
of small breast tumors, vacuum-assisted biopsy systems have been proposed 
and are increasingly introduced in clinical practice. Vacuum-assisted biopsy has 
great potential in (MRI-guided) breast biopsy. When vacuum-assisted breast 
biopsy is performed, more tissue is sampled compared with the amount of 
tissue removed with LCNB. This would probably outweigh the negative effect 
of the larger needle artifact caused by the use of a larger biopsy needle in 
vacuum-assisted biopsy. However, vacuum-assisted biopsy is not available 
in all institutions yet and, to our knowledge, no study has directly compared 
the diagnostic accuracy of LCNB with a vacuum-assisted biopsy system in a 
randomized controlled trial.
We found 19 benign (66%), one inconclusive biopsy result (3%) and nine 
(31%) malignant lesions. These numbers correspond to the 35%, 34% and 25% 
malignant lesions reported in comparable studies [8-10]. The studies by Kuhl 
et al. [8] and Fisher et al. [9] reported 98% (77/78) of the biopsy samples to be 
representative with the use of a 14G needle [8] and 89% (25/28) using an 18G to 
22G biopsy needle [9]. The 97% (28/29) representative results we found using 
a 14G core biopsy are comparable with the results described by Kuhl et al. [8]. 
In our study, two benign lesions turned out to be malignant at follow-up. The 
second lesion was a lobular carcinoma in situ, which was surgically removed. 
One LCIS lesion was surgically removed, and additional DCIS and a small (<4 mm)
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invasive ductal carcinoma were found at histopathological examination of the 
lump. The other lesion showed a more malignant kinetic enhancement curve at 
12-months follow-up MRI. Because of the change in lesion characteristics, the 
lesion was sampled again and an invasive lobular carcinoma was found. Given 
the change in enhancement characteristics and the relatively long period of 
follow-up, it remains unclear whether the lobular carcinoma developed during 
follow-up or should be considered as a missed malignancy. For this reason the 
MRI BI-RADS lexicon committee recommend a 6-month breast-MRI follow-up 
after MRI-guided biopsy.
Currently, only one study has been published on breast imaging at high field 
strength: Kuhl et al. [8] reported a prospective intra-individual comparative 
study performed on 37 patients with 53 enhancing breast lesions who 
underwent contrast-enhanced breast MRI at 1.5T and 3T. The high resolution 
of the 3T images allowed depiction of lesion morphology with unprecedented 
accuracy [11], suggesting a promising role for 3T breast MRI. In this patient 
series, we used 14G titanium biopsy needles. Large-core needles (14G) are 
recommended for percutaneous biopsy of breast lesions to ensure sampling 
of sufficient tissue [12]. However, larger needles cause larger susceptibility 
artifacts on MR images. Furthermore, susceptibility artifacts increase with 
increasing field strength. This can cause a substantial signal void around the 
14G biopsy needle when performing MRI-guided breast biopsy at 3T, especially 
when the biopsy needle is placed perpendicular to the main magnetic field, 
as is usually the case in MRI-guided breast biopsy [9]. Our study showed that a 
signal void of 9.5 mm can be achieved at 3T. To our knowledge, no reports on 
MRI-guided breast biopsies at 3 T are available. The extent of the signal void of 
comparable studies were 4 mm (1.5 T, 14G needle) [8], 5 mm (0.5T, 16G needle)
[9] and 10 mm (ultra-fast scan protocol) [9], which is smaller than the signal 
void we found at 3T, as was expected. However, the 9.5-mm signal void did not 
reduce the accuracy of the tissue sampling. The previously mentioned studies 
reported a diagnostic accuracy of 98% (58/59) [8]. Fisher et al. [9] did not report 
the diagnostic accuracy of their patient series.
In conclusion, MRI-guided 14G core-needle biopsy at 3T is a safe and effective 
method for breast biopsy in lesions that are occult on mammography and 
ultrasound. In the case of benign biopsy results, a 6-month follow-up MRI 
should be performed.
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MRI-guided breast biopsy at 3T using 
a dedicated large core biopsy set: 
Feasibility and initial results
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Abstract
Objective
The increasing importance of breast MRI in the diagnostic processes concerning 
breast cancer
yield often lesions that are visible on MRI only. To assess the nature of these 
lesions, pathologic analysis is necessary. Therefore, MR-guided biopsy should 
be available. Breast MRI at 3T has shown advantage over 1.5T. Unfortunately, 
current equipment for MR-guided biopsy is better suited for intervention at 1.5T 
due to the danger of heating titanium co-axial sleeves and large susceptibility 
artifacts. We evaluated a dedicated 3T breast biopsy set that uses plastic coaxial 
needles to overcome these problems.
Materials and methods
We performed MRI-guided breast biopsy in 23 women with 24 MRI-only visible 
breast lesions at 3T. Biopsy procedures were performed with plastic coaxial 
needles in a closed bore 3T clinical MR system on a dedicated phased array 
breast coil with a commercially available add-on stereotactic biopsy device.
Results
Width of the needle artifact was 2 mm in all 24 cases. Biopsy procedure was 
completed between
35 and 67 min. The procedure was judged moderately easy in 12 and normal 
in 10 cases. One procedure was judged difficult and there was one technical 
failure.
Conclusion
MRI-guided breast biopsy at 3T is a fast and accurate procedure. The plastic 
coaxial needles
reduce the susceptibility artifact largely and do not increase the difficulty of the 
procedure. The diagnostic yield is at least equal to the diagnostic yield of the 
same procedure at 1.5T. Therefore, this technique can be safely used for lesions 
only visible at 3T MRI.
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Introduction
The use of MRI for the detection and evaluation of breast lesions continues to 
increase. With a sensitivity of around 90% it is a more sensitive method than 
mammography or ultrasound for the detection of breast cancer [1]. A recent 
meta-analysis showed the pooled-weighted specificity to be 72%, with a 
95% confidence interval of 67-77% [1]. Approximately 10-20% of patients 
with a malignant breast lesion detected on mammography has an additional 
malignancy that is mammographically and ultrasonographically occult [2,3]. 
When these additional suspicious breast lesions are detected on MR images, 
histopathological analysis is required. MRI-guided tissue sampling of these 
"MRI-only lesions" can be accomplished by means of wire localization and 
surgical excision, vacuum biopsy, or by large core-needle biopsy (LCNB) [4]. 
Large core-needle biopsy has several advantages over wire localization, 
including decreased invasiveness, morbidity, and costs [5,6]. MRI-guided 
breast biopsy performed at 1.5T, using a 14G MRI-compatible needle, has 
been reported to have 98% diagnostic accuracy [7]. Some authors do not 
recommend MRI-guided core biopsy for lesions < 10mm, because the results are 
often inconclusive [5,8]. Nevertheless, the demand for biopsy of suspect sub­
centimeter MRI-only lesions is high. MRI systems operating at high magnetic 
fields strengths (e.g. 3T) become increasingly available in the clinical setting. 
Some studies have shown advantage of 3T breast MRI over 1.5T breast MRI in 
lesion detection and classification [9]. It is undoubtedly true that imaging at 
3T allows a higher spatial resolution and consequently smaller lesions can be 
detected. Unfortunately, the current equipment for MR-guided biopsy is better 
suited for intervention at 1.5T due to the danger of heating titanium co-axial 
sleeves and the large susceptibility artifacts that results from the use of these 
co-axials. Only one article described MRI-guided large core-needle biopsy at 
3T of 32 suspicious breast lesions on 3T using a 14G MRI-compatible titanium 
needle and found a signal void of 9.5mm [10]. We evaluated a dedicated 3T 
breast biopsy set that uses plastic coaxial needles to overcome these problems.
Materials and methods
Patient characteristics
Twenty-three women (mean age; range: 52; 27-73 years) with 24 suspicious 
breast lesions which were only detected by MRI (MRI-only) were examined 
between May 2007 and February 2008. Indications for diagnostic breast MRI 
were problem solving (n = 5), increased risk of breast cancer (n = 7), preoperative
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staging (n = 3) and unknown (n = 8). Patients were referred for MRI-guided 
biopsy from 8 different hospitals. All 24 lesions were at least 5 mm in size and 
were classified as BI-RADS 3 (n = 8), BI-RADS 4 (n = 15) or BI-RADS 5 (n = 1) on 
earlier MRI evaluations.
MRI-guided biopsy procedure and equipment
Second-look ultrasound was obtained in all patients; if the lesion could be 
retrieved on ultrasound images, ultrasound-guided biopsy was performed; if 
the lesion was occult on ultrasound images, MRI- guided biopsy was performed. 
We used a 4-channel breast coil (Invivo interventional instruments, Wurzburg, 
Germany) with a dedicated add-on device for breast biopsy (Noras, Germany) 
that allows lateral access, positioning of the needle-guide in the x and y planes 
and angulation up to 30° around the x axis (Figure 1). After positioning of the 
patient in the breast coil, the breast to be investigated was compressed to obtain 
optimal fixation. We obtained a sagittal image of the biopsy device to detect 
the fiducial markers within the device and subsequently obtained four high 
resolution Fast Low Angle Shot (FLASH) 3D acquisitions of the whole breast, 
one prior to and three after the administration of 0.2 mmol/kg contrast agent 
(DOTAREM, Guerbet, France). The main parameters of this MR sequence are 
listed in Table 1. We used a dedicated workstation (DynaCAD, Invivo, Germany) 
to locate the lesions and obtain the coordinates for needle positioning (Figure
2). Subsequently the breast was disinfected and anaesthetized. A small incision 
was made in the skin and the 12G coaxial needle 9 (Coax Needle Highfield 12 
G- 11.1mm Invivo interventional instruments, Wurzburg, Germany) was placed 
using a titanium trocar. The trocar was replaced by a plastic rod (MRI Needle 
Sleeve 12G Invivo interventional instruments, Wurzburg, Germany) and with 
this in situ one more FLASH 3D acquisition was obtained. The position of the 
coaxial needle was compared to the position of the lesion and in case of good 
correlation up to eight biopsies were taken clockwise, using a disposable 14G 
semi-automatic Highfield MRI compatible biopsy gun (Invivo interventional 
instruments, Wurzburg, Germany).
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Table 1 . Biopsy protocol
TE/TR (ms) 2.62/735
Flip angle 13°
Fat suppression none
Field of view (mm2) 340 x 170
Effective slice thickness (mm) 1
Number of acquistions 1 prior and 3 after contrast medium
Number of slices 160 / acquisition
Acquired voxel size (mm3) 0.9 x 0.9 x 1
Temporal resolution (s) 2.5
Figure 1. Add-on biopsy device for 4 channel open breast coil.
Feasibility of the technique
Feasibility of this technique was scored by an experienced registered breast 
radiologist, based on earlier experience. Before this study was taken place 
already more than 50 LCNB were performed by this radiologist. The difficulty 
of the procedure was scored on a five-point scale ranging from easy (score 1), 
moderately easy (score 2), normal (score 3), to difficult (score 4) and technical 
failure (score 5).
79
Chapter 6
Figure 2 . The work-station provides the exact biopsy coordinates (left lower corner).
Data collection
After histopathological analysis, the lesions were classified in two categories: 
benign or malignant. In case of a benign lesion, the images of the biopsy 
procedure were re-evaluated to determine whether the tissue samples were 
representative. If the samples were considered not representative, follow up, 
a second biopsy or surgical excision was performed (either in house, or at the 
referring hospital), based on the level of suspicion of malignancy and patients' 
preferences. Malignant lesions were surgically removed.
Results
We performed biopsies of 24 lesions in 23 women. The shortest procedure was 
completed within 35 min, the longest took 1 h (mean: 45 min; range: 35-67 
min).
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The difficulty of the procedure, scored on a five-point scale ranging from easy 
to difficult, was judged moderately easy in 12 and normal in 10 cases (Table 2). 
One procedure was judged moderately difficult due to fainting of the patient 
and one was rated a technical failure. Median lesion size was 12mm (range 
5-27) (Table 3). The width of the needle artifact was 2mm in all cases, which 
allowed perfect evaluation of the placement of the coaxial needle. A typical 
example of the acquired images during the procedure is shown in Figure 3. The 
coaxial needle was placed directly in front of the lesion immediately in 21 of 
24 cases, in 2 cases one further manipulation was needed, in 1 case adequate 
positioning was not possible. The mean number of biopsies taken was 4.9 
(range 2-7). Nineteen biopsies yielded pathologic results that could explain the 
visible lesion. In 4 patients only normal breast tissue was found (Table 3).
Table 2 . Feasibility of this technique
Score Numbers of procedures Biopsy time (minutes)
Score 1: easy 0 -
Score 2: moderately easy 12 43
Score 3: normal 10 46
Score 4: difficult 1 60
Table 3. Histopathological findings and lesion size in 24 breast lesions
Number Lesion size (mm)
Malignant and high risk lesions 9 (38%)
- atypical ductal hyperplasia (ADH) 1 11
- atypical lobular hyperpasia (ALH) 1 9
- invasive ducto-lobular carcinoma 2 5, 8
- ductal carcinoma in situ (DCIS) 3 14, 8, 15
- invasive ductal carcinoma (IDC) 1 27
- colloidcarcinoma 1 24
Benign lesions 12 (50%)
- fibrosis 7 Median: 11
- fibroadenoma 2 8, 13
- masthopathy 1 10
- scar lesion 1 19
- pseudo-angiomatose stromal hyperplasia 1 6
Unrepresentative 4 (17%) 9, 9, 11, 7
Total 24 Median: 12
We found 12 benign (50%), 4 inconclusive biopsy result (17%) and 9 (38%) 
malignant lesions. The inconclusive biopsies were all of relatively low suspicion 
and underwent follow up elsewhere and showed no signs of malignancy after
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follow-up (Tables 3 and 4). Table 4 and Figure 4 show the pathological findings 
after chirurgical excision or after 6 months to 2 years follow up in the 24 lesions.
Figure 3. Biopsy procedure of a small lesion (arrow), with the coaxial needle in place (black line) 
These small lesion can be assessed accurately, using the dedicated 3T co-axial needles. This 
lesion proved to be a small scar lesion.
Table 4. Histopathological findings after chirurgical excision biopsy or follow-up MRI
Number
Histopathology excision biopsy or 
follow-up MRI
Malignant lesions
- invasive ducto-lobular carcinoma 2 Invasive ducto-lobular carcinoma 
with DCIS
- ductal carcinoma in situ (DCIS) 2 DCIS grade 3
- ductal carcinoma in situ (DCIS) 1 IDC with DCIS
- invasive ductal carcinoma (IDC) 1 IDC with DCIS
- colloidcarcinoma 1 colloidcarcinoma
High risk lesions
- atypical ductal hyperplasia (ADH) 1 ADH with DCIS
- atypical lobular hyperpasia (ALH) 1 ALH without invasive carcinoma
Benign lesions BI-RADS 1
- fibrosis 7 Fibroadenoma
- fibroadenoma 2 BI-RADS 1
- masthopathy 1 Invasive lobular carcinoma
- scar lesion 1 BI-RADS 1
- pseudo-angiomatose stromal hyperplasia 1
Unrepresentative: normal breast tissue 4 BI-RADS 1
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7 (29%) malignant lesions Chirurgical excision biopsy: 7 malignant lesions
Chirurgical excision biopsy: 1 malignant lesion
2 (8%) high risk lesions
Chirurgical excision biopsy: 1 high risk lesion
4 (17%) non-representative lesions Follow-up MRI: no signs of malignancy (n=4)
Figure 4. MRI-guided LCNB, histopathological results and follow-up MRI.
Figure 5. One technical failure due to inability to adequately position the co-axial needle. The 
lesion was an area of wash-out in a known scar (image shows subtraction (left) and T1 with color 
coded enhancement information (right)), due to prior lumpectomy 10 years earlier. Compression 
and fixation of the breast was hardly possible due to severe fibrosis. It was impossible to get the 
co-axial sheet in position. At surgery, the lesion turned out to be a recurrent ILC.
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Discussion
We report our preliminary experience in MRI-guided large core- needle breast 
biopsies using a 3T closed bore clinical MRI system. In our patient series, MRI- 
guided large core-needle biopsy was technically successful in 96% of patients 
(23/24). Only one procedure was judged difficult, due to fainting of the patient. 
We had one technical failure due to inability to adequately position the co- axial 
needle. The lesion was a hotspot in a known scar, due to prior lumpectomy 10 
years earlier. Compression and fixation of the breast was hardly possible due 
to severe fibrosis (Figure 5). It was almost impossible to get the co-axial sheet 
in position. The lesions were judged as a scar lesion after LCNB. At surgery, 
the lesion turned out to be a recurrent invasive lobular carcinoma (ILC). The 
diagnostic accuracy of MRI-guided LCNB is in this series of patients 92% (22 of 
24). One high risk lesion was upgraded to a malignant lesion, the lesion with 
atypical ductal hyperplasia (ADH) contained also a ductal carcinoma in situ 
(DCIS) component after chirurgical excision biopsy (Table 3 and Figure 4). One 
lesion with DCIS contained also a invasive ductal carcinoma IDC component 
after chirurgical biopsy.
Currently, only one study has been published on breast imaging at high field 
strength: Kuhl et al. reported a prospective intra- individual comparative study 
performed on 37 patients with 53 enhancing breast lesions who underwent 
contrast-enhanced breast MRI at 1.5T and 3T. The high resolution of the 3T 
images allowed depiction of lesion morphology with unprecedented accuracy
[9], suggesting a promising role for 3T breast MRI.
In this patient series, we used 14G titanium biopsy needles. Large core­
needles (14 G) are recommended for percutaneous biopsy of breast lesions to 
ensure sampling of sufficient tissue [11]. However, larger needles cause larger 
susceptibility artifacts on MR images. Furthermore, susceptibility artifacts 
increase with increasing field strength. This can cause a substantial signal void 
around the 14G biopsy needle when performing MRI-guided breast biopsy 
at 3T, especially when the biopsy needle is placed perpendicular to the main 
magnetic field as is usually the case in MRI-guided breast biopsy [8]. Peters et al. 
showed that a signal void of 9.5mm can be achieved at 3T with titanium needles
[10]. However, the 9.5mm signal void did not reduce the accuracy of the tissue 
sampling. To our knowledge, no other reports on MRI-guided breast biopsies 
are available at 3T. The small needle artifact (only 2mm in all cases in our study), 
allowed perfect evaluation of the placement of the coaxial needle. The extent 
of the signal void in comparable stud- ies of dedicated biopsy needles for MRI 
at lower field strengths were 4mm(1.5T, 14G needle) [7], 5mm(0.5T, 16G needle) 
[8] and 10mm (ultra fast scan protocol) [8], respectively, which is larger than the
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signal void we found at 3T.
Some lesions cannot be sampled because these lesions are in a difficultly 
accessible location in the breast. In the most proximal and the most distal 
parts of the breast adequate compression is difficult to achieve, which makes 
introduction of the biopsy needle not feasible. We advise to pursue MRI-guided 
breast biopsies even in these areas of the breast. If tissue sampling turns out 
not to be feasible, follow-up MRI is advised (to assess growth or change in the 
dynamic enhancement curve) or MRI-guided needle localization followed 
by surgical excision of the lesions depending on the level of suspicion of 
malignancy. MRI-guided needle localization can be done stereotactic or by 
a freehand technique [12,13]. To increase the diagnostic accuracy of tissue 
sampling of small breast tumors, vacuum biopsy systems have been proposed 
and are increasingly introduced in clinical practice. However, to our knowledge 
no study evaluated the diagnostic accuracy of vacuum biopsy system at 3T. 
MRI-guided breast biopsy at 3T is a fast and accurate procedure. The plastic 
coaxial needles reduce the susceptibility artifact largely and do not increase 
the difficulty of the procedure. The diagnostic yield is at least equal to the 
diagnostic yield of the same procedure at 1.5T [14]. Therefore, this technique 
can be safely used for lesions only visible at 3T MRI.
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MR-guided breast biopsy at 3T: 
diagnostic yield of large core 
needle biopsy compared with 
vacuum-assisted biopsy.
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Abstract
Objective
The purpose of this study was to evaluate two MR-guided biopsy techniques 
at 3T, large core needle breast biopsy (LCNB) and vacuum-assisted breast 
biopsy (VAB) and to compare the diagnostic yield and rate of complications to 
determine the optimal biopsy technique at T.
Methods
70 LCNB and 72 VAB were consecutively performed. Benign biopsy results were 
verified by retrospective correlation of histology, with pre-interventional, post­
interventional MRI studies and follow-up and were classified as representative 
or non-representative. Time to follow-up was up to 2 years for the considered 
non-representative benign lesions. Statistical analysis was performed using the 
Chi-squared test.
Results
LCNB was technically successful in 99% of patients (69/70) and VAB in 96% 
of patients (69/72). Histopathological analysis resulted in 55 (79%) benign, 7 
(10%) high-risk and 8 (11%) malignant lesions for LCNB and 51 (71%) benign,
3 (4%) high-risk and 18 (25%) malignant lesions. Vacuum-assisted biopsy was 
significantly more often representative than LCNB (p = 0.01). Distribution was 
significantly different (p<0.001), favouring VAB over LCNB.
Conclusion
Because of the substantially higher diagnostic yield and certainty of a benign 
diagnosis, VAB is the optimal biopsy technique at 3T. LCNB should be considered 
when VAB is not feasible.
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Introduction
The use of Magnetic Resonance Imaging (MRI) for the detection and evaluation 
of breast lesions continues to increase. MRI of the breast has high sensitivity 
and lower specificity in the evaluation of breast lesions, with sensitivity of 90% 
and a specificity of 72% [1].
The increasing use of magnets with high field strength (3 Tesla [T] and over) 
in clinical practice is very suitable. With the high signal-to-noise ratio of these 
systems, appropriate acquisitions can be used to achieve high spatial and 
temporal resolution that allows depiction of lesion morphology and lesion 
enhancement with unprecedented accuracy [2-4]. Compared with the results 
of 1T and 1.5T MRI in the literature, 3T may have an even higher sensitivity to 
breast cancer [5]. Nevertheless, even at 3 T it is often not possible to separate 
malignant from benign findings purely on imaging characteristics alone. 
Accurate diagnosis of these lesions requires histological evaluation.
Magnetic resonance imaging of the breast reveals suspicious lesions occult at 
target ultrasound or mammography in about 44% of the cases [6,7]. In these 
suspicious MRI breast lesions MRI-guided biopsy is the technique of choice. 
Moreover, MRI-guided biopsy is indicated in all lesions where an ultrasound 
or mammographically detected and biopsied lesion is possibly not the same 
lesion as that detected at MRI. The demand for MRI-guided breast interventions 
is growing owing to the increasing use of breast MRI in clinical practice. 
Magnetic resonance-guided tissue sampling of suspicious MRI breast lesions, 
can be accomplished by fine-needle aspiration, wire localisation followed 
by surgical excision, large core-needle biopsy (LCNB), or by vacuum-assisted 
biopsy (VAB) [8,9].
Magnetic resonance-guided LCNB using 14G needles and VAB have both been 
described as suitable techniques for MRI-guided breast biopsy at 1.5T [10-21]. 
At 3T only MRI-guided LCNB has been evaluated [22,23]. Moreover, no studies 
directly compare the diagnostic yield of LCNB with VAB at any field strength. 
In this retrospective study we evaluated both methods at 3T and compared 
the diagnostic yield and rate of complications to determine the optimal biopsy 
technique at 3T.
Materials & Methods
Patient characteristics
Patients derive from a diagnostic population, who presented with an MRI- 
detected lesion between July 2007 and February 2010, not visualised at
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second-look ultrasound or in whom second-look ultrasound could not reliably 
reproduce the lesion, were scheduled for MRI-guided biopsy at 3 T. Before 
October 2008 14G LCNB were performed, thereafter 9G VAB was the principal 
method. We retrospectively analysed the data from a total of 147 consecutive 
women (mean age; range: 51; 29-71 years) with 155 suspicious breast lesions at 
our hospital, in this period. Indications for breast MRI are shown in Table 1. Patients 
were referred for MRI-guided biopsy from 22 different hospitals. Patients with 
a breast MRI from a different hospital, had a second reading from a MRI-breast 
radiologist in our institution, before the biopsy. In doubtful cases an additional 
diagnostic breast-MRI was performed in our institution.
The level of suspicion was reported on a scale of 0-6, identical to that in 
the lesion-assessment categories used in the breast imaging reporting and 
data system (BI-RADS) [24]. Numeric categories were the following: 0, needs 
additional imaging evaluation; 1, normal; 2, benign; 3, probably benign; 
4, suspicious; 5, highly suggestive of malignancy; 6 proven malignancy. 
Classification was based on lesion morphology and enhancement kinetics [25]. 
For lesions interpreted as probably benign, suspicious or highly suggestive 
of malignancy on MRI, correlative ultrasound was performed to determine if 
the lesion was ultrasonographically evident and, thereby amenable to tissue 
sampling under ultrasound guidance. All patients with a BIRADS 3, 4 or 5 lesions 
that were ultrasonographically occult were scheduled for a MRI-guided breast 
biopsy. In 80% of the biopsied cases there was a mass lesion, in 12% of the 
biopsied cases there was non mass like enhancement and in 8% of the cases 
there was a focus.
All MRI-guided breast biopsies were performed in a clinical setting. The study 
has been carried out in the Netherlands in accordance with the applicable rules 
concerning the review of research ethics committees and informed consent.
Table 1. Indication for MRI examination in 147 patients
Number
High risk screening 54 (37%)
- positive family history or BRCA positive 48
- history of high risk lesion or cancer 6
Problem solving 43 (29%)
- questionable lesion mammography / ultrasound 36
- positive axillary node, unknown primary 7
Staging of known breast cancer 50 (34%)
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MRI-guided biopsy procedure and equipment
All biopsies were performed on a Siemens Magnetom Trio system, using a 
dedicated four-channel open breast coil (Invivo Interventional Instruments, 
Wurzburg, Germany), with an add-on device for needle positioning (Noras, 
Germany).
Patients were positioned on the MRI table in the prone position with the 
affected breast compressed in the biopsy device to avoid motion during the 
biopsy procedure. All patients underwent imaging before and three times after 
the administration of 0.1 mmol/kg contrast agent (DOTAREM, Guerbet, France), 
using a T1-weighted Fast Low Angle Shot (FLASH) 3D acquisition that lasted 98 
s and provided coverage of both breasts with near isotropic voxels of 0.9*0.9*1 
mm to allow image reconstruction in any plane. The main parameters of this 
MRI sequence are listed in Table2. A dedicated computer program (DynaCAD, 
Invivo, Germany) was used to obtain coordinates of the lesion and guidance for 
needle positioning (Figures 1 and 2). After initial imaging, the table was moved 
out of the bore and local anaesthesia (lidocaine 1%) was administered after 
disinfection of the breast. A small incision was made in the skin and the needle 
(LCNB or VAB) was inserted into the breast. The position of the device was 
evaluated with a FLASH 3D and another FLASH 3D was obtained immediately 
post-biopsy to correlate the biopsy cavity (at LCNB) and the marker (at VAB, 
ATEC TriMark, Indianapolis, IN, USA) with the position of the lesion.
Table 2 . Biopsy protocol 
TE/TR (ms)
Flip angle 
Fat suppression 
Field of view (mm2)
Effective slice thickness (mm)
Number of acquisitions 
Number of slices 
Acquired voxel size (mm3)
Temporal resolution (s)
2.62/735 
13° 
none 
340 x 170 
1
1 prior and 3 after contrast medium 
160 / acquisition 
0.9 x 0.9 x 1 
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MRI-guided large core needle biopsy
Large core-needle biopsy was performed with 14G titanium needles using a 
post and pillar system that allowed angulation of the biopsy tract up to 30°
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(Figure 3). Through a sterile 12G needle holder a 12G coaxial needle was inserted 
in the breast (CoaxNeedle Highfield 12G-11.1 mm; Invivo Interventional 
Instruments). In the event of good correlation the patient was moved out of the 
bore of the magnet. Between 2 and 6 biopsies were taken with a disposable 14G 
semi-automatic Highfield MRI compatible biopsy gun (Invivo Interventional 
Instruments).
Figure 1. Screenshot from a biopsy procedure, using a 14G large core needle to biopsy an non­
mass-like area of enhancement in the upper outer quadrant of the left breast. The lower screen 
shows how to position the post and pillar device. The coordinates for optimal needle position 
can be read from the bottom of the screen.
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Figure 2 . Screenshot from a biopsy procedure using a 9G vacuum-assisted needle to biopsy a 
small mass-like lesion with an irregular margin at six o'clock in the left breast. The lower screen 
shows where to put the needle block (purple square) and which hole to use (orange dot) in order 
to come closest to the optimal position (red circle). The required depth can be read at the bottom 
of the screen (arrow).
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Figure 3. Post and pillar biopsy system with LCB system in place, note that the needle is angulated 
towards the thoracic wall. The blue device at the post and pillar system is a needle sleeve that 
can be used to lock the co-axial needle in one position when the biopsy needle is inserted and 
removed to obtain multiple samples.
MRI-guided vacuum-assisted biopsy
Vacuum-assisted biopsy were performed with one of two commercially 
available MRI-compatible VAB devices: either a 10-gauge VAB system (SenorRx; 
Irvine, CA, USA) or a 9-gauge VAB system (ATEC Suros, Indianapolis, IN, USA). We 
used a grid system with a needle block as supplied by the manufacturer; this 
approach did not allow angulation (Figure 4).
A coaxial sheath was placed using a 9G or 10G titanium stylet in the appropriate 
grid location. The stylet was replaced by a sterile plastic MRI-visible obturator. 
If a FLASH 3D proved a good correlation, the plastic obturator was replaced by 
one of the respective VAB devices and up to 12 biopsies were taken.
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Figure 4.Grid system with VAB system in place, note that no angulation is possible. The computer 
program indicates where to put the needle block and which hole to use to perform the most 
accurate biopsy.
Data Collection and statistic analysis
Of the 14y patients with suspicious breast lesions, 4 patients had two lesions 
and 2 patients had three lesions. Thirteen lesions were biopsied twice with 
the same technique VAB or LCNB. Two VAB procedures who were scheduled 
as a VAB were converted to LCNB and only accounted as a VAB and were not 
accounted as a LCNB. A total of 168 suspected lesions were scheduled for an 
MRI-guided biopsy, 41 BIRADS 3 lesions, 112 BIRADS 4 lesions and 16 BIRADS 5 
lesions. In 26 patients the procedure was cancelled and finally we performed y0 
LCNB and y2 VAB in a consecutive series of patients scheduled for MRI-guided 
breast biopsy (Figure 5). Of the y2 VAB, 39 biopsies were performed with the 
10G VAB system (SenorRx) and the other 33 biopsies were performed with a 9G 
VAB system (ATEC Suros).
All biopsies were performed by three experienced MRI-breast radiologist who 
had a lot of experience with MRI-guided LCNB and less with MRI-guided VAB. 
We assessed technical success rates, where technical success was defined as:
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1. It is possible to get the needle on the right spot
2. The biopsy can be safely performed according to the performing physician
3. The lesion was removed completely or partially according to the post-VAB 
imaging.
We judged VAB not possible, if the risk of skin tears, severe bleeding, or severe 
pain in the patient was high. Complications, such as pain and arterial bleeds 
were registered and were in this study not considered as technical unsuccessful. 
After histopathological analysis, the lesions were classified in three categories: 
benign, high-risk or malignant. Malignant lesions and high-risk lesions were 
surgically removed. In the case of a benign lesion, the images of the biopsy 
procedure were re-evaluated to determine whether the tissue samples were 
representative and at least 6-month follow-up MRI was recommended. 
Subsequently the representativeness of the specimen for the lesion was assessed, 
for example if there was enough breast tissue and is the quality of the specimen 
good enough to make a reliable specific diagnosis. Results were classified as 
representative or non-representative. If the samples were considered not 
representative, follow-up and/or a second biopsy was performed. Total time to 
follow-up was 2 years in case of unchanged lesions.
Statistical analysis was done with SPSS 12.0 and using the Mann-Whitney U test. 
Significance was assumed at a level of p <0.05.
Results
Technical success
In our patient series, LCNB was technically successful in 99% of patients (69/70) 
and VAB was technically successful in 96% of patients (69/72) (n.s.).
According to the post-interventional imaging 1 of the 72 VAB procedures was 
unsuccessful and immediate rebiopsy was performed. Two VAB procedures 
were converted to LCNB because the performing physician judged VAB not 
safely possible. One of these lesions was too close to the skin and the other 
lesion was too close to the chest wall. In another patient scheduled for LCNB a 
14G needle could not enter the breast because of the solid consistency of the 
breast. Finally a successful biopsy was performed with an 18G needle. 
Assessment was considered impaired, but successful in 1 LCNB procedure 
and 3 VAB procedures (n.s.). Motion artefacts occurred in 1 patient at LCNB. 
Histological analysis of the lesion revealed normal breast tissue. After more 
than 1 year of follow-up, no signs of malignancy were found.
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Using VAB 2 small arterial haemorrhages that required prolonged manual 
compression were recorded (Figure 5). In one patient no marker could be placed 
because the patient could no longer lie in the prone position.
The lesion size ranged from 3 to 28 mm with a median lesion size of 12 mm, 
48% were smaller than 1 cm (31 LCNB and 38 VAB) and 8% of all the lesions were 
smaller than 5 mm (foci) and were all biopsied with MRI-guided VAB. Eight of 
the 14 non-representative LCNBs were smaller than 1 cm (57%) and one of the
4 non-representative VABs was smaller than 1 cm.
Figure 5. Biopsy of a small irregular lesion at 6 o'clock in the left breast using a 9G vacuum 
assisted needle. A: subtraction image created prior to the biopsy procedure to localize the 
lesion. B: placement of the coaxial sheet, the trocar has been removed and replaced with a 
plastic insert. C: the same coaxial sheet directly after the biopsy, note the large hematoma that 
surrounds the tip of the needle (double headed arrow). D: A large marker is left that also provides 
some compression from the inside. Pathology revealed a complex sclerosing lesion with cystic 
degeneration. No malignancy was found.
Clinical results
Final histology results obtained in 70 LCNB and 72 VAB procedures are listed 
in Table3. In the LCNB group histopathological analysis of the biopsy samples 
resulted in benign lesions in 55/70 (79%), in high-risk lesions in 7/70 (10%) and 
in malignant lesions in 8/70 (11%). In the VAB group this resulted in 51/72 (71%) 
benign lesions, 3/72 (4%) and 18/72 (25%) malignant lesions (Figure 6). Follow- 
up data were available for 98 of the 106 (92%) benign biopsies.
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Table 3. Histological findings
LCNB VAB
(n=70) (n=72)
Lesion findings No. % No. %
Malignant 8 11 18 25
- IDC 3 4 10 14
- ILC 3 4
- DICS 4 6 5 7
- Other 1 1
- High-risk 7 10 3 4
- LCIS 3 4 3 4
- ADH 2 3
- ALH 2 3
Benign 55 79 51 71
- Fibroadenoma 3 4 5 7
- Sclerosing adenosis 4 6 5 7
- Lymph node 2 3 1 1
- Radial scar 3 4 2 3
- papilloma 1 1
- Normal breast tissue 26 37 14 20
- Others 16 23 24 34
IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; DCIS: Ductal Carcinoma In 
Situ; LICS: Lobular Carcinoma In Situ; ADH: Atypical Ductal Hyperplasia; ALH: Atypical Lobular 
Hyperplasia
Figure 6.FlowchartMRI-guidedbiopsiesandhistopathologicalresults.
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Representativeness of the specimen
Vacuum-assisted biopsy was significantly more often representative than LCNB 
(p = 0.01, (Mann-Whitney U test)). Fifty-seven (81%) of the LCNBs were judged to 
be representative (8 malignant, 3 high-risk and 45 benign lesions) and 14 (20%) 
were considered to be not representative (4 high-risk and 10 benign lesions) 
(Table 4). Three patients with unrepresentative benign findings were lost to 
follow-up. Sixty-nine (96%) of the VABs were judged to be representative (18 
malignant, 3 high-risk and 48 benign lesions) and 3 (4%) were not considered 
not to be representative (Table 4). One patient with unrepresentative benign 
findings was lost to follow-up (Figure 7). Finally 5 of the 7 considered not 
representative benign lesions after LCNB were proven malignant lesion after 
surgical excision biopsy and 2 of 3 considered not representative benign lesions 
after VAB were proven malignant lesions after surgical excisional biopsy. Four 
high-risk lesions after LCNB were upgraded to malignant lesions after surgical 
excisional biopsy (Table 5).
Table 4. Representative and non-representative lesions
LCNB (70 lesions) VAB (72 lesions)
Malignant 
(8 lesions)
High-risk Benign 
(7 lesions) (55 lesions)
Malignant 
(18 lesions)
High-risk 
(3 lesions)
Benign 
(51 lesions)
Representative lesions 8 3 45 18 3 47
Non-rep esentative 
lesions 0 4 10 0 0 4
142 b iopsies
Figure 7. Flowchart showingrepresentativeandnon-representativelesionsofthe143 biopsied 
lesions.
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Table 5. Histopathology of non-representative lesions
Non-representative lesionsHistology after MRI-guided biopsy Final histology after surgical excision
biopsy
LCNB (n=14) Benign: Benign:
1. Fibrosis 1. Spindle cell lipoma
Lost to follow-up (n=3) 2. Normal breast tissue 2. Apocrine metaplasia
3. Normal breast tissue
Malignant:
3. Colloid carcinoma
4. Normal breast tissue 4. DCIS
5. Fibrosis 5. IDC
6. Fibrosis 6. IDC and DCIS
7. Epidermal inclusion cyst 7. ILC
High-risk lesion:
8. ALH 8. ILC
9. ALH 9. DCIS and LCIS
10. ADH 10. IDC
11. ADH 11. Apocrine carcinoma
VAB (n=4) Benign: Benign:
1. Normal breast tissue 1. Fibroadenoma
Lost to follow-up (n=1)
2. Normal breast tissue
Malignant:
2. DCIS
3. Normal breast tissue 3. IDC
Discussion
We evaluated LCNB and VAB using a 3T scanner and compared the diagnostic 
yield and rate of complications to determine the optimal biopsy technique at 
3T.
Published data on the use of MRI-guided biopsy at 1.5T reported a technical 
success rate of 95% to 100% and cancer yields ranging from 20% to 56% for 
LCNB [10,11,15], and a technical success rate of 96% to 100% and cancer yields 
ranging from 24% to 40% for VAB [16-21]. These numbers are comparable to the 
accepted rates reported in mammography- and ultrasound-guided procedures 
[8]. In our patient series, in the LCNB group 11% were found to be malignant 
after biopsy and 25% in the VAB group. LCNB was technically successful in 
99% of patients (69/70) and VAB was technically successful in 96% of patients 
(69/72), but more importantly VAB was significantly more often representative 
than LCNB.
Magnetic resonance-guided LCNB using 14G needles at 1.5T have been 
reported by several groups [10-15]. Kuhl et al. [10] reported the largest 
series of MRI-guided LCNB in 59 patients with 78 lesions. One carcinoma was
102
Diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy
missed, and histological underestimations were not observed. Chen et al. [11] 
reported 34 successful LCNB in 35 lesions in 29 women and 6% (2/35) were 
underestimated carcinoma. Two lesions with atypical ductal hyperplasia were 
upgraded to malignancy after surgery. In a multicentre European trial Perlet 
et al. [18] reported successful VAB in 517 (96%) of 538 lesions. Histological 
underestimation was observed in 8 patients (2%). An upgrade was noted in 5 
patients who had a diagnosis of ADH, and in 3 patients who had a diagnosis of 
DCIS.
In our study 20% of the LCNB were considered unrepresentative biopsies. After 
chirurgical excision biopsy 7% of carcinomas were missed (5/70) and histological 
underestimation was present in 6% (4/70). VAB showed 4 (6%) unrepresentative 
biopsies, 2 (3%) missed carcinomas and histological underestimation was not 
observed.
The chance of detecting malignancy is very much dependent on the a priori 
chance of the biopsied lesion being malignant. It is important to realise that 
it is essential to compare the results of the pathological analysis of the biopsy 
specimen with the lesion seen at MRI. A diagnosis of fibrosis with chronic 
inflammation is usually acceptable in lesions with no mass effect classified as 
BI-RADS 3 to BI-RADS 4a. However, this diagnosis is absolutely insufficient in 
lesions classified as BI-RADS 5, as well as in any lesion presenting as a clear mass. 
Magnetic resonance-guided LCNB using 14G needles and VAB have both been 
described as suitable techniques for MRI-guided breast biopsy at 1.5 T [8,9], 
although several potential limitations of LCNB have been described at 1.5T or 
lower [9]. Compared with 1.5T, at 3T an extra potential limitation of the LCNB 
technique has been described by Peters et al. [22]. Susceptibility artefacts 
increase with increasing field strength. This can cause a substantial signal void 
around the 14G needle when performing MRI-guided LCNB at 3T.
The certainty of the histopathological diagnosis increases with an increase in 
the amount of tissue extracted, especially in a situation where there is no real­
time feedback of the needle position during biopsy, as is the case in MRI-guided 
breast biopsy. In lesions with no mass effect LCNB may not sample enough 
material to ascertain diagnosis. In mass lesions the non-rigid breast tissue may 
allow a small solid lesion to move during biopsy, causing the needle to pass right 
beside the lesion, rather than through its core. In our study 48% of the biopsied 
lesions were smaller than 1 cm. Eight of the 14 non-representative LCNB were 
smaller than 1 cm (57%). Therefore, LCNB biopsy at 3T is not recommended for 
lesions smaller than 10 mm. However 2 VAB procedures were converted to LCNB 
because of the location of the lesion, which is in part attributable to the more 
rigid biopsy technique with the grid system. Using angulation of the needle will 
probably allow VAB in a number of patients in whom the technique first failed.
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Our study has several limitations. First of all, unfortunately we did have some 
patients with unrepresentative biopsy findings who were lost to follow-up.
A more important limitation of this study is the fact that the two biopsy 
techniques were compared in a sequential and not in a parallel way. Lots 
of covariates could influence the results of the two study arms, the most 
important being the fact that experience was much higher for the second 
biopsy technique, resulting in a much steeper learning curve and possibly 
better results. Also the fact that two different vacuum assisted biopsy devices 
have been used is another potential limitation as the study subgroup becomes 
heterogeneous.
Another very important limitation is the highly heterogeneous study population. 
The fact that patients were referred from 22 different hospitals for MRI-guided 
biopsy and the consecutively study population is a major limitation. Although 
all breast MRI's from the different hospitals, had a second reading from a MRI- 
breast radiologist in our institution, prior to the biopsy and in doubtful cases 
an additional diagnostic breast MRI was mad in our institution, it is unthinkable 
that equal clinical guidelines for such referrals apply for all hospitals or that 
experience levels match for all those different radiologists.
Finally, by the time we started with MRI-guided LCNB at 3T, large core needles 
with 14G were not anymore recommended for MRI-guided biopsy at 1.5T [8, 9]. 
Compared with the results of 1T and 1.5T MRI in the literature, 3T may have 
higher sensitivity in the detection of breast cancer [5]. Nevertheless the 
specificity is comparable with the results of 1.5T [5]. Demand for adequate MRI- 
guided tissue sampling remains, also at high field strength. Our study shows 
that MRI-guided VAB should be used for all MRI-guided breast biopsies at 3T 
because of the substantially higher diagnostic yield and increased certainty of a 
benign diagnosis, compared with LCNB. LCNB should be considered when VAB 
is unavailable or not feasible.
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Breast MRI is a very promising tool based on its extremely high sensitivity in 
revealing breast cancer. Multiple studies confirm that MRI can depict cancer 
that is occult to physical examination, mammography and ultrasound [1-4]. 
However, a major limitation is the low-to-moderate specificity range from 67% 
to 77% [5].Due to the moderate specificity the technique is prone to induce 
unnecessary biopsies and overtreatment. The best safeguard against such 
unnecessary interventions is not to perform breast MRI when it is not indicated.
The current guidelines published by the American College of Radiology (ACR) 
and the guidelines from the European society of breast imaging (EUSOBI 
committee) recommend breast MR in the following circumstances [6, 7]:
1. Screening for the high-risk patient (BRCA 1 or 2 mutations or patients with 
a 20% or greater lifetime risk).
2. Screening the contralateral breast in a patient with a recently diagnosed 
breast malignancy.
3. Following patients with neoadjuvant chemotherapy.
4. Evaluation for recurrence of breast cancer (exclusion of local recurrence 
after breast-conserving therapy).
5. Problem solving in case of inconclusive findings on conventional imaging 
or an unknown primary carcinoma.
And only the ACR guidelines:
6. Screening in patients with breast augmentation (for example in patients 
with postoperative reconstruction).
7. Estimation of disease extent in patients with invasive carcinoma or ductal 
carcinoma in situ (DCIS)
8. Assessment of invasion in the deep fascia.
9. Evaluating residual disease extent post lumpectomy with positive margins.
Currently, in our country only screening of high-risk patients, following patients 
treated with neoadjuvant chemotherapy and 'problem solving' are indications 
for performing breast MRI [8]. Also pre-operative staging of breast cancer in 
selected cases a breast MRI can be performed [8], although the value of this 
indication is discussed (see below).
In my opinion, indications 2, 4, 6, 7 and 9 could be questioned:
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6. Screening in patients with breast augmentation (for example in patients with 
postoperative reconstruction).
Screening MR may be helpful in patients with augmentation but no comparison 
study between mammography and MRI is found. Handel concluded in a review 
of 4082 breast cancer patients (129 augmented) treated over a 23-year time 
span that conventional mammography is a very reliable tool for diagnosing 
early breast cancer in augmented patients [9]. In patients with breasts injected 
with foreign material (paraffin or silicone injection), MRI could be the diagnostic 
method of choice to detect malignancy, because of the poor visualization at 
mammography [10]. For breast implant rupture MRI is a more accurate method 
than mammography or ultrasound [11].
2. Screening the contralateral breast in a patient with a recently diagnosed breast 
malignancy and
7. Estimation of disease extent in patients with invasive carcinoma or DCIS.
Despite the massive evidence that breast MRI is better in assessing disease 
extent in women with breast cancer than conventional methods such as 
mammography and ultrasound, it may be difficult to use this information to 
improve the quality of surgery. For example, a recent Dutch study showed that 
breast MRI should not be used routinely for preoperative work-up of patients 
with nonpalpable breast cancer. Addition of MRI to routine clinical care in 
patients with nonpalpable breast cancer was paradoxically associated with an 
increased re-excision rate in this study [12]. Moreover it is so far not proven that 
the detection of second tumors in the contralateral breast in approximately 
25% of women [13, 14] justifies the large amount of additional interventions 
for false positive findings. A survival benefit of MRI detected synchronous 
contralateral cancers over early metachronous detection of secondary tumors 
by mammographic surveillance of treated breast cancer patients has until now 
not been shown.
4. Evaluating residual disease extent post lumpectomy with positive margins.
If there is a small amount of residual disease, the patient might benefit from 
re-excision before radiation therapy. If extensive residual disease remains in 
the breast, mastectomy might be the treatment of choice [15]. MRI has been 
suggested as an adjunctive imaging technique to identify residual breast cancer 
[16], but postsurgical contrast enhancement resulting from inflammatory 
changes at the site of surgery limits the accuracy of breast MRI. Frei et al. 
recommend scheduling patients with positive resection margins no earlier than 
28 days after initial surgery for evaluation of residual cancer using MR imaging 
of the breast [17]. It seems unreasonable to delay necessary surgical treatment
111
Chapter 8
for more than 4-5 weeks considering the marginal gain of test performance 
of MR imaging of the breast more than 28 days after surgery, especially in 
patients with fast-growing tumors. Information of the extent and location of 
residual disease might influence the surgeon's choice between re-excision and 
mastectomy. Additionally, MR imaging may identify areas for specific surgical 
attention and offer the surgeon a "road map" at re-excision.
9. Evaluating residual disease extent post lumpectomy with positive margins.
Several studies have shown benefits of MR in differentiating scar versus 
recurrence at the lumpectomy site in patients in whom mammography is 
indeterminate [18-20]. The literature where to the ACR is referred is dated. The 
quality of mammography has greatly improved and has shown its value, also 
in the evaluation for recurrence of breast cancer [21]. To my knowledge there 
aren't recent randomized controlled trails who compare mammography and 
breast MRI in the evaluation of recurrent breast cancer. Therefore more research 
is needed to find out if breast MRI is a good indication in this group of patients. 
Until that time women with dense breasts and lumpectomy an MRI may be 
considered.
In conclusion, in my opinion screening for the high-risk patient, following 
patients with neoadjuvant chemotherapy and 'problem solving' are good 
indications for performing breast MRI. Screening the contralateral breast in a 
patient with a recently diagnosed breast malignancy, evaluation for recurrence 
of breast cancer, screening in patients with breast augmentation, estimation 
of disease extent in patients with invasive carcinoma or DCIS and evaluating 
residual disease extent post lumpectomy with positive margins are in my 
opinion only an indication in selected cases. In these patients it is important to 
look at individual features, for example patient risk factors, clinical history, age 
and whether there are inconclusive findings on conventional imaging. This, to 
avoid unnecessary biopsies and patients worries.
Another solution to avoid unnecessary biopsies is to increase the specificity of 
breast MRI. One of the tools that might possibly improve the specificity of breast 
MRI is the use of computer-aided-diagnosis (CAD) programs. Unfortunately, in 
a recent published meta-analysis were they evaluated the additional value of 
CAD in breast MRI, CAD had little influence on the sensitivity and specificity 
(sensitivity without CAD: 89% and with CAD: 89%, specificity without CAD: 
86% and with CAD: 82%). Only residents or inexperienced radiologists seem 
to benefit from CAD concerning breast MRI evaluation [22]. Up to now also 
scanning at 3T seems not to improve the specificity. The specificity at 3T is
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comparable with the results of 1.5T. So far, only the sensitivity at 3T might be 
slightly higher when compared to the results in literature with a 1T/1.5T scanner 
[23].
Optimal methods for performing contrast-enhanced imaging at 3T have not 
been achieved, given potential problems from decreased B1 homogeneity [24]. 
Developing an improved breast protocol for 3T requires further research as 3T 
breast imaging becomes more widely used. Also at 3T it is often not possible 
to separate malignant from benign findings purely on imaging characteristics 
alone. Therefore, a demand for adequate MR guided tissue sampling remains, 
also at high field strength. Different biopsy techniques at 3T were examined in 
this thesis to find the optimal biopsy technique for this high-field-strength MRI 
system.
In the literature different MRI-guided breast biopsy techniques are described 
at 1.5T or lower. MRI-guided wire localization has an overall success rate of 97% 
(range, 91% - 100%) and the cancer yield averages 37% (range, 0%-80%) [25­
42]. However, this means that many unnecessary operations are performed 
for benign findings. Wire localization is associated with higher morbidity and 
financial costs compared to minimal invasive procedures such as LCNB and VAB 
[43]. For these reasons MRI-guided wire localization cannot be recommended as 
the primary method nowadays. Exceptions are difficult accessible breast lesions 
(including those in the anterior retroareolar region, those deeply localized near 
the chest wall, and lesion localizations in patients with silicone implants [44]) 
only visible on MRI, as described in chapter 4. When there is no MRI-guided 
biopsy equipment available, the patient should be referred to a specialized 
center where they do have this equipment.
Published data on the use of MRI-guided biopsy at 1.5T reported a technical 
success rate of 95% to 100% and cancer yields ranging from 20% to 56% 
for LCNB [45-47] and a technical success rate of 96% to 100% and cancer 
yields ranging from 24% - 40% for VAB [48-53]. The percentage missed or 
underestimated carcinomas was 4% (ranging from 0% - 15%) for both LCNB and 
VAB [45-53]. These numbers are comparable with the accepted rates reported 
in mammography- and ultrasound-guided procedures [26], but were prior to 
the studies presented in this thesis not available for MRI guided biopsy at 3T. 
MRI guided biopsy is most often used for the evaluation of BIRADS IV lesions (2­
95% chance of malignancy) for which a malignant rate of 30% to 50% is reported 
in studies with mammographically or ultrasonically guided biopsy [17]. BIRADS 
V lesions (>95% chance of malignancy) can most of the time be visualized with 
ultrasound, because of the size and morphology and therefore ultrasound 
guided biopsy should be performed. In one of our studies (see chapter 7) 
where we evaluated 142 lesions, only 14% of the lesions were BIRADS V lesions.
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For BIRADS III (probably benign) lesions, at mammography a 6-month short­
term follow-up is recommended, because the frequency of carcinoma in these 
lesions is low, ranging from 0.5% to 2% [54-57]. Published results show a wide 
range of cancer yields (0.6% to 10%) among probably benign MRI lesions [58­
63]. There are a few indications for which mammographic stereotactic biopsy of 
BIRADS III lesions may be considered, such as when follow-up is compromised 
or not available, in the instance of planned pregnancy, or for patient anxiety 
[55, 64-66], indications that also hold true for MR guided breast biopsy. In 
our study 18% of all the MRI-guided biopsied lesions were BIRADS III breast 
lesions, because a lot of women nowadays do not except a 6 month follow-up 
and prefer a biopsy directly. The largest group of BIRADS III lesions in our study 
was composed of foci (54%), by definition lesions smaller than 5 mm. One %  of 
these lesions were malignant and another 2% were classified as high risk lesions 
at pathologic analysis. Prior research indicates that the risk of malignancy in 
suspicious lesions smaller than 5 mm is less than 3% [67]. The final decision 
regarding biopsy recommendation should be based not only on lesion size but 
on other lesion features (e.g., morphology, kinetics, and enhancement pattern) 
and patient risk factors and clinical history [67]. Lesions too small to classify 
usually have a very small a priori risk of being malignant and, in my opinion, 
should in most instances be neglected and not biopsied. In this thesis, I have 
assessed the possibility to increase the specificity of breast MRI at 3T by using a 
dedicated CAD program. However, since it is evident that 100% specificity can 
only be achieved by tissue analysis, most of this thesis is dedicated to assessing 
the optimal biopsy technique at 3T with respect to invasiveness and diagnostic 
yield. In the following paragraphs a summary of these findings is presented.
In Chapter 2 we evaluated the accuracy of 3T breast MRI interpretation using 
manual and fully automated kinetic analyses to determine the diagnostic 
performance of CAD to differentiate between malignant and benign lesions. 
CAD datasets were interpreted by two experienced breast radiologists and two 
residents. Using threshold enhancement alone, the sensitivity and specificity 
of CAD were 97.9% and 86.4%, respectively, for the 50% threshold and 97.9% 
and 90%, respectively, for the 100% threshold. Manual interpretation by two 
breast radiologists showed a sensitivity of 84.6% and a specificity of 68.8%. For 
the same two radiologists the mean sensitivity and specificity for CAD-based 
interpretation improved to 90.4% (not significant) and 81.3% (significant at 
p < 0.05), respectively. With one-way ANOVA no significant differences were 
found between the two breast radiologists and the two residents together, 
or between any two readers separately. Our findings suggest that computer- 
aided evaluation has the potential to improve the discrimination of benign
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from malignant breast lesions at MR imaging. However it should be noted that 
this study only focused on analyzing mass lesions and not the non-mass-like 
enhancing lesions. The specificity of DCE-MRI is, in general, much lower for the 
diagnosis of non-mass-like enhancement when compared with masses [68-69]. 
Approximately 30% of invasive lobular cancer [70] and DCIS [58, 71] show low 
initial enhancement with a persistent kinetic pattern. More research is needed 
to investigate methods developed for the characterization of the morphology 
and kinetic features of both mass and non-mass lesions.
In Chapter 3: Different MRI-guided biopsy techniques are reviewed, including 
MRI-guided wire localization using a freehand technique, wire localization using 
a stereotactic technique and MRI-guided large core needle biopsy. Three cases 
are described of women with ultrasonically occult lesions. In a woman with an 
ultrasonically occult breast tumor which was only visible in one direction on 
mammography MRI-guided needle localization of the lesion followed by surgical 
excision biopsy was carried out for diagnostic purposes. In a second woman, 
mammographic needle localization of a deep, ultrasonically occult, lesion 
was unsuccessful. She then also underwent MRI-guided needle localization 
followed by surgical excision biopsy. A third woman with known carcinoma 
underwent a MRI staging study. This revealed a second, mammographically and 
ultrasonically occult, lesion for which MRI-guided large-core needle biopsy was 
done. The first lesion revealed a benign lymph node after pathologic analysis. 
The suspicious lesion of the second woman revealed an adenocarcinoma and 
the third woman had a multifocal invasive ductal carcinoma. In this last case, a 
planned breast conserving therapy was converted into a radical mastectomy. 
In the first case an operation could be avoided if a MRI-guided LCNB had been 
performed instead.
Chapter 4: is a feasibility study of free-hand wire localization in difficult to access 
regions of the breast. MRI-guided needle localizations are described that were 
performed on five patients using a freehand technique. All suspicious breast 
lesions, located in difficult to access regions of the breast were successfully 
localized with this technique. Histopathologic evaluation of tissue after surgical 
excision biopsy revealed one lymph node, three invasive ductal carcinomas 
and one ductal carcinoma in situ. Mean duration was 25 min. No complications 
occurred during the interventions. In the patient with the benign lesion, control 
MRI of the breast after 6 months confirmed lesion removal. Although this was 
a pilot study with limited number of patients, the findings suggest that this 
localization technique is feasible, fast and accurate (100%) in a closed bore 
magnet for diagnosis of difficult accessible breast lesions only visible on MRI. 
The cancer yield of MRI-guided wire localization averages 37% [28]. This means 
that many unnecessary operations are performed for benign findings. Wire
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localization with the freehand technique can nevertheless be performed and 
may be the method of choice for lesions that are far posterior and not included 
in a grid or far anterior where compression may be suboptimal.
Chapter 5: is a report of our preliminary experience in MRI-guided large-core- 
needle breast biopsies using a 3T closed-bore clinical MRI system. Thirty-one 
suspicious breast lesions shown only by MRI were detected in 30 patients. 
Tissue sampling was technically successful in 29/31 (94%) lesions. Two lesions 
could not be sampled since both lesions were located in a poorly accessible 
location within the breast. In one patient a 9-mm lesion was located directly 
posterior to the mammilla and in another patient a 9-mm lesion was located 
directly anterior to the thoracic wall. Histopathological analysis showed 19 
benign lesions (66%) and one inconclusive biopsy result (3%). At follow-up of 
these 19 patients with benign lesions, 15 lesions showed no malignancy, no 
information was available in three patients and two lesions turned out to be 
malignant. Nine biopsy results showed a malignant lesion (31%) which were all 
surgically removed.
Large core-needles (14 G) are recommended for percutaneous biopsy of breast 
lesions to ensure sampling of sufficient tissue [72]. However, larger needles 
cause larger susceptibility artifacts on MR images. Furthermore, susceptibility 
artifacts increase with increasing field strength. This can cause a substantial 
signal void around the 14G biopsy needle when performing MRI-guided breast 
biopsy at 3T, especially when the biopsy needle is placed perpendicular to the 
main magnetic field, as is usually the case in MRI-guided breast biopsy [37]. Our 
study showed that a signal void of 9.5 mm can be seen at 3T. The susceptibility 
artifacts could be kept within limits by careful choice of the scan sequence 
parameters and did not reduce the accuracy of the tissue sampling. It can be 
concluded that MRI guided 14G core-needle biopsy at 3T is a safe and effective 
method for MRI-only lesions, but still fails to diagnose all malignant lesions 
correctly since 2 of 19 benign biopsy results (10%) turned out to be malignant. 
Chapter 6: evaluated the use of a dedicated large core biopsy set for 3T MRI. MRI- 
guided breast biopsies were performed on 23 women with 24 MRI only visible 
breast lesions. Biopsy procedures were performed with plastic coaxial needles 
in a closed bore 3T clinical MR system on a dedicated phased array breast coil 
with a commercially available add-on stereotactic biopsy device. Width of the 
needle artifact was 2 mm in all 24 cases. The procedure was judged moderately 
easy in 12 and normal in 10 cases. One procedure was judged difficult and 
there was one technical failure. The plastic coaxial needles greatly reduce the 
susceptibility artifact and do not increase the difficulty of the procedure. The 
diagnostic accuracy of MRI-guided LCNB is in this series of patients 92% (22 
of 24). The diagnostic yield is at least equal to the diagnostic yield of the same
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procedure at 1.5T. Therefore, this technique can be safely used for lesions only 
visible on a 3T MRI.
Chapter 7: aims to determine the optimal biopsy technique at 3T. MRI-guided 
LCNB and VAB at a 3T scanner were evaluated and the diagnostic yield and 
rate of complications were compared. Sixty-one of the 70 (87%) LCNB were 
judged representative (8 malignant, 5 high risk and 48 benign lesions) and 9 
(13%) were not representative (after surgical excision biopsy: 2 benign and 6 
malignant lesions). One patient was lost to follow up. Sixty-nine of the 72 (96%) 
VAB's were judged representative (18 malignant, 3 high risk and 48 benign 
lesions) and 3 (4%) were not representative (after surgical excision biopsy: 1 
benign and 2 malignant lesions). Using VAB 2 small arterial hemorrhages that 
required prolonged compression were recorded and 2 biopsy procedures were 
converted to LCNB because the performing physician judged VAB unsafe to 
perform. Using LCNB no complications were recorded. Given the increased 
diagnostic yield of VAB at 3T, the slightly higher chance of complications 
(bleeding) using VAB is acceptable. We believe that when feasible, VAB should 
be the biopsy method of choice at 3T. LCNB may be performed when VAB is not 
feasible. LCNB biopsy is not recommended for lesions smaller than 10 mm at 
3T because 8 of the 14 non-representative LCNB were smaller than 1 cm (57%). 
Comparable with the mammographic biopsy results [73] and the results at 
1/1.5T VAB is the optimal biopsy technique at 3T. MRI-guided LCNB should 
be considered when VAB is unavailable or not feasible. MRI-guided wire 
localization, using the "freehand" technique is only recommended for difficult 
to access breast lesions that are situated deeply posterior in the breast and not 
included in a grid or extremely anterior where compression may be suboptimal. 
In summary, the moderate low specificity of breast MRI is still an important 
issue. Demand for adequate MR guided tissue sampling remains, also at high 
field strength. Breast MRI at 3T does not yet improve specificity and more 
research is still needed to improve the specificity of this modality. Our findings 
suggest that CAD has the potential to improve the discrimination of benign 
from malignant breast mass lesions at MR imaging, but more research is needed 
to investigate methods developed for the characterization of the morphology 
and enhancement kinetic features of both mass and non-mass lesions.
Until the perfect breast cancer vaccine, new advances in breast cancer imaging 
will improve our ability to detect early-stage disease. Because of the early 
detection of small breast carcinomas, there has been an increasing interest 
in treatment with minimally or even noninvasive imaging-guided methods. 
Examples of these new modalities are MR spectroscopy, and nuclear medicine 
sestamibi imaging using technetium-99m methoxyisobutyl isonitrile or positron 
emission tomography (PET) techniques which provide information beyond that
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of structural imaging by displaying tumor neoangiogenesis, tumor metabolites, 
increased numbers of tumor cellular mitochondria, and hypermetabolic tumor 
cells [74-76]. Much needs to be learned at the molecular level of normal cellular 
pathways either suppressed or enhanced by tumor-specific molecular changes. 
These discoveries may allow realization of true individualized patient tumor 
detection, treatment, and surveillance. The latest developments towards a 
less invasive breast cancer treatment include image-guided breast cancer 
ablation by means of laser ablation [77], radiofrequencency ablation [78-79], 
cryoablation [80] and focused ultrasound ablation [81]. Most of the studies that 
have evaluated these techniques have examined a limited number of cases, 
and long-term follow-up information is absent. Again, further investigation is 
required in this field.
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The use of MRI for the detection and evaluation of breast lesions continues to 
increase. The reason is the high sensitivity of MRI compared with mammography 
and ultrasound for the detection of breast malignancy. There is also an increase 
in the use of MRI scanners with high field strengths (3T) in clinical practice. 
Because of the high sensitivity of an MRI breast scan it is possible to detect 
suspicious lesions in the breast that are clinically, mammographically and 
ultrasonically occult. However, the specificity of breast MRI is limited. Due to 
this limitation, a MRI-guided biopsy is sometimes the only way to achieve a 
definitive diagnosis of these lesions.
Comparing the results in literature of scans made on a 1T and 1.5T MRI scanner 
to those made with a 3T MRI scanner show that a 3T MRI may have a higher 
sensitivity in the detection of breast cancer. Nevertheless the specificity is 
comparable with the results of 1.5TMRI scan. Even with scanning at high field 
strengths the demand remains for adequate MR guided tissue sampling 
In the literature different MRI-guided breast biopsy techniques are described 
using a 1.5T scanner. Tissue sampling of these "MRI-only lesions", can be 
accomplished either by wire localization followed by surgical excision, large 
core-needle biopsy (LCNB), or by vacuum-assisted biopsy (VAB).
In the first part of this thesis a Computer-Aided-Diagnosis system is evaluated 
for the evaluation of suspicious breast lesions found using a 3T MRI scanner 
to increase specificity. In the second part different MRI-guided breast biopsy 
techniques are evaluated using a 3T scanner.
In Chapter 2 we compare the consistency and accuracy between manual and 
fully automated kinetic analyses in the interpretation of a 3T breast MRI.
Using a CAD-based analysis the specificity was significantly improved compared 
with manual analysis. Automated analysis at 50% and 100% thresholds showed 
a high sensitivity and specificity for evaluators with varying levels of experience, 
but could not obviate the need for biopsy.
In chapter 3, three cases are described of women with ultrasonically occult 
lesions. In this review different MRI-guided biopsy techniques are described at 
3T, MRI-guided wire localization using a freehand or stereotactic technique and 
MRI-guided large core needle biopsy.
In chapter 4 pilot results of the MRI-guided wire localization, using a freehand 
method, are presented. Of all the different techniques available an MRI-guided 
wire localization followed by surgical excision is still considered the gold 
standard for tissue sampling, especially for small and difficult to access breast 
lesions. Needle localizations using a freehand method were performed on 5 
patients. All lesions were located outside the grid or acceptable compression 
was not possible. Four lesions were localized near the thoracic wall and one
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near the nipple. Histopathologic evaluation revealed one benign and four 
malignant lesions. No complications occurred during the intervention. Thus 
MRI-guided needle localization using a freehand technique in a 3T closed bore 
magnet is a safe and accurate method for diagnosis of difficult to access breast 
lesions only visible on MRI.
Because of the more invasive technique and high costs of MRI-guided wire 
localization followed by surgical excision, MRI-guided large core needle biopsy 
has been developed. The results of this technique are described in chapter 5. 
A disadvantage of this method are the susceptibility artifacts caused by the 
metal introduction sheath which can obscure small lesions (<5 mm), resulting 
in possible difficulty to perform accurate biopsy of these lesions. These 
susceptibility artifacts increase with increasing field strength (3.0T and higher). 
However, in this study the 9.5 mm susceptibility artifact caused by the 14G 
titanium biopsy needle had no negative effect on the procedure.
In chapter 6 we evaluated the use of plastic coaxial needles instead of titanium 
needles for breast biopsy to overcome the problems of large susceptibility 
artifacts. The use of plastic coaxial needles greatly reduced susceptibility artifacts 
and does not increase the difficulty of the procedure. A needle susceptibility 
artifact of only 2 mm was achieved. The diagnostic yield using a plastic needle 
at 3T is comparable to the diagnostic yield of the same procedure at 1.5T using 
a titanium needle. However, benign biopsy results (normal breast tissue) did 
not rule out the possibility of malignancy to an acceptable level.
In chapter 7 we evaluated MRI-guided LCNB and VAB and compared the 
diagnostic yield and rate of complications to determine the optimal biopsy 
technique using a 3T scanner. VAB samples more tissue than LCNB. Consequently 
VAB may have a higher diagnostic yield.
There were slightly more complications using VAB, whilst MRI-guided LCNB 
had a higher rate of non-representative lesions. Given the fact, that the slightly 
higher chance of complications (bleeding) using VAB is acceptable in relation 
to the increased diagnostic yield, we strongly suggest, that when feasible VAB 
should be the biopsy method of choice even at 3T. LCNB may be performed 
when VAB is not feasible.
In summary, because of the substantial higher diagnostic yield and certainty 
of a benign diagnosis, VAB is the most optimal biopsy technique at 3T. LCNB 
should be considered when VAB is unavailable or not feasible. MRI-guided wire 
localization, using the "freehand" technique is recommended only for difficult 
to access breast lesions. Our findings suggest that CAD has the potential to 
improve the discrimination of benign from malignant breast mass lesions at MR 
imaging, but more research is needed to investigate methods developed for 
the characterization of the morphology and enhancement kinetic features of 
both mass and non-mass lesions.
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In Nederland wordtjaarlijks bij ca. 12.000vrouwen borstkanker gediagnostiseerd. 
De kans op het krijgen van borstkanker is gedurende het leven van een vrouw 
12-13%. Hiermee is borstkanker in Nederland de meest voorkomende vorm 
van kanker bij vrouwen. Voor beeldvorming van de borst zijn mammografie en 
echografie de meest gebruikte methoden. Naast deze gangbare methodes kan 
er in sommige gevallen gekozen worden voor een MRI scan. Redenen hiervoor 
kunnen onder andere zijn: het screenen van hoogrisicopatiënten, analyse van 
onduidelijke afwijkingen die gezien zijn op het conventionele mammogram 
of bij echografie, follow-up van patiënten na borstsparende behandeling en 
evaluatie van respons op neoadjuvante chemotherapie. De specificiteit van 
MRI van de borst is echter beperkt, met andere woorden niet iedere afwijking 
die gevonden wordt in de borst is kanker. Mede hierdoor wordt MRI van de 
borst klinisch altijd gebruikt als aanvulling op het standaard mammogram, 
dat het huidige onderzoek van eerste keus is voor borstkankerdiagnostiek. 
MRI heeft als voordeel dat de sensitiviteit ten opzichte van mammografie en 
echografie veel hoger is, want vrijwel alle kwaadaardige tumoren in de borst 
worden gevonden met MRI. Hierdoor wordt MRI als beeldvormende techniek in 
toenemende mate gebruikt voor analyse en detectie van tumoren in de borst. 
Ook het gebruik van MRI scanners met een hogere veldsterkte (3 tesla en meer) 
neemt in de kliniek toe. Door de hoge sensitiviteit kan MRI-onderzoek een 
suspecte afwijking detecteren in de borst die zowel klinisch als mammografisch 
en echografisch niet zichtbaar is. Vanwege de suboptimale specificiteit van dit 
onderzoek is een MRI-geleide biopsie helaas vervolgens de enige manier om 
tot een definitieve diagnose van de afwijking te komen.
Vergeleken met de resultaten uit de literatuur over MRI-onderzoek van de borst 
uitgevoerd op 1 en op 1.5 tesla scanners heeft een 3 tesla scanner mogelijk 
een hogere sensitiviteit. Desalniettemin is de specificiteit vergelijkbaar met 
de resultaten uitgevoerd op een 1.5 tesla scanner. Ondanks het scannen op 
een hogere veldsterkte blijft de noodzaak tot het uitvoeren van MRI-geleide 
biopsiën dus bestaan.
In de literatuur zijn verschillende MRI-geleide biopsie technieken beschreven 
die uitgevoerd zijn op 1.5 tesla scanners. Deze technieken bestaan uit dunne 
naald biopsie, draadlokalisatie gevolgd door chirurgische excisie biopsie, dikke 
naald biopsie en vacuüm biopsie.
Dit proefschrift bestaat uit twee delen. In het eerste deel wordt een computer 
analyse systeem geëvalueerd bij de evaluatie van suspecte laesies in de borst 
die gedetecteerd zijn op een 3 tesla MRI scanner met als doel te evalueren of met 
dit systeem een hogere specificiteit kan worden bereikt. Vervolgens worden, 
in het tweede deel verschillende MRI-geleide biopsie technieken beschreven, 
allen uitgevoerd op 3 tesla scanners.
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Behalve de relatief lage specificiteit van borst MRI is de aanzienlijke tijd die 
nodig is voor beeldverwerking en interpretatie een groot nadeel. Computer- 
aided detectie (CAD) algoritmen zijn ontwikkeld voor automatische 
verwerking en kinetische analyse, die voorheen handmatig uitgevoerd door 
MRI-technologen en radiologen. Op het moment, dat een radioloog op het 
systeem een verdachte laesie heeft geselecteerd, creëert CAD automatisch 
een rapport met referentie beelden, grootte en locatie van de laesie en een 
"breast imaging reporting and data system (BIRADS)-rapport" voor iedere 
afwijking. Aan de hand van verschillende kleuren (die corresponderen met 
contrastopname en uitscheiding) in een afwijking laat dit systeem zien of 
een afwijking verdacht is voor kanker of niet. In hoofdstuk 2 vergelijken we de 
consistentie en accuraatheid van de interpretatie van MRI-onderzoeken van de 
borst (allen vervaardigt op 3 tesla scanners), tussen handmatige en volledig 
geautomatiseerde kinetische analyse. Met behulp van het CAD systeem was 
er een significant toegenomen specificiteit in vergelijking met de handmatige 
analyse. De geautomatiseerde analyse toont een significant hogere sensitiviteit 
en specificiteit voor beoordeelaars met uiteenlopende niveaus in ervaring. 
Niettemin blijft er voor bepaalde afwijkingen toch de noodzaak tot MRI geleide 
biopsie bestaan.
In hoofdstuk 3 worden 3 patiënten besproken, 3 vrouwen met een 
echografische niet zichtbare afwijking. In dit Nederlandse overzichtsartikel 
worden verschillende (MRI-)geleide technieken besproken zoals de MRI- 
geleide vrijehand-draadlokalisatie, de stereotactische draadlokalisatie en de 
MRI-geleide dikke naald biopsie.
In hoofdstuk 4 wordt de MRI-geleide vrijehand-draadlokalisatie besproken. Van 
alle MRI-geleide biopsie technieken is de MRI-geleide draadlokalisatie gevolgd 
door chirurgische excisie de gouden standaard, met name voor hele kleine 
afwijkingen en afwijkingen die moeilijk te benaderen zijn. Draadlokalisatie 
volgens de "vrijehand"- methode werd uitgevoerd bij 5 patiënten, bij wie de 
afwijking zich buiten het biopsie-rooster bevond of bij wie het borstweefsel 
niet goed te comprimeren was. Vier afwijkingen bevonden zich direct tegen 
de borstwand aan en één bevond zich direct achter de tepel. Histologisch 
onderzoek liet 1 goedaardige en 4 kwaadaardige afwijkingen zien. Er traden 
geen complicaties op. MRI-geleide draadlokalisatie met een "vrijehand" 
-methode bleek aldus een veilige en nauwkeurige methode te zijn voor de 
diagnose van moeilijk benaderbare afwijkingen, die alleen zichtbaar zijn op 
MRI waren.
Gezien het invasieve karakter en de hoge kosten van de draadlokalisatie- 
technieken gevolgd door de chirurgische excisie, is een zogenaamde MRI- 
geleide dikkenaald biopsie ontwikkeld. Dit is een techniek waarbij de patiënt
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in buikligging op de mammaspoel plaats neemt en de borst gefixeerd wordt 
tussen een biopsierooster aan de buitenkant en een compressieplaat aan 
de binnenkant. Na berekening van de juiste introductieplaats en plaatselijke 
verdoving van de huid, wordt een introductienaald, door een geleider heen, 
vanaf lateraal de borst in gebracht tot aan de tumor. Uiteindelijk wordt buiten 
de magneet door de introductienaald de biopsienaald geplaatst en worden 
de biopten genomen. De resultaten van deze techniek wordt beschreven 
in hoofdstuk 5. Een nadeel van deze methode is de metaalartefacten van de 
introductienaald, waardoor kleine afwijkingen (< 5 mm) niet meer zichtbaar zijn, 
wanneer de introductienaald zich over de laesie projecteert. Hierdoor kunnen 
de laesies niet nauwkeurig gebiopteerd worden. Deze metaalartefacten nemen 
toe bij de toenemende veldsterkte (bij 3 tesla en hoger). In deze studie had het 
metaalartefact, veroorzaakt door de titanium 14G naald een afmeting van 9.5 
mm, hetgeen geen invloed had op de kwaliteit van de procedure.
In hoofdstuk 6 wordt een MRI-geleide dikkenaald biopsie techniek besproken, 
die gebruik maakt van plastic in plaats van titanium introductienaalden. 
Hiermee worden de naaldartefacten gereduceerd tot 2 mm. De resultaten 
van MRI-geleide dikkenaald biopsie gebruikmakend van de plastic introductie 
naalden op 3 tesla scanners bleken vergelijkbaar met MRI-geleide dikkenaald 
biopsie gebruikmakend van titanium naalden op 1.5 tesla scanners.
In hoofdstuk 7 wordt de diagnostische waarde en complicatiekans van MRI- 
geleide vacuüm biopsie en de MRI-geleide dikkenaaldbiopsie met elkaar 
vergeleken. Bij MRI-geleide vacuümbiopsie is de kans op complicaties iets 
groter en. Bij de MRI-geleide dikkenaaldbiopsie is er daarentegen sprake van 
niet-representatief materiaal. De gering verhoogde kans op complicaties 
(bloedingen) bij MRI-geleide vacuümbiopsie wordt, zeker gezien de grotere 
betrouwbaarheid als acceptabel beschouwd. MRI-geleide vacuüm biopsie 
wordt daarom geadviseerd als eerste keus van MRI-geleide biopsie techniek op 
een 3 tesla scanner. MRI-geleide dikkenaald biopsie kan daarentegen worden 
uitgevoerd wanneer MRI-geleide vacuümbiopsie niet haalbaar is.
Samengevat, vanwege de aanmerkelijk hogere diagnostische opbrengst 
en de zekerheid van een benigne diagnose is MRI-geleide vacuüm biopsie 
de meest optimale biopsie techniek op een 3 tesla scanner. MRI-geleide 
dikkenaaldbiopsie moet alleen worden overwogen wanneer vacuüm biopsie 
niet beschikbaar of uitvoerbaar is. MRI-geleide draadlokalisatie, met behulp 
van de "vrije hand" -methode wordt aanbevolen voor moeilijk toegankelijke 
afwijkingen in de borst. Onze bevindingen suggereren dat CAD de potentie 
heeft om goedaardige en kwaadaardige borst massa's goed van elkaar te 
onderscheiden, maar meer onderzoek is nodig om ook de morfologische 
eigenschappen van een goedaardige en kwaadaardige laesie van elkaar te
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onderscheiden. Op dit moment kunnen alleen massa's redelijk goed van elkaar 
worden onderscheiden met behulp van CAD, maar in een borst kunnen ook 
maligniteiten voorkomen die zich niet presenteren als een massa, maar meer 
als een diffuse afwijking. Mogelijk zal hierdoor het aantal onnodige biopsieën 
afnemen.
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zonder jou onverwijlde steun en liefde dit traject nooit tot een goed einde had 
kunnen brengen. Ongekend hoe jij de opvoeding van onze twee kleintjes bijna 
geheel op je eigen schouders hebt genomen en daarnaast je eigen bedrijf en 
de huishouding hebt bestierd.
Lieve Bjorn en Merel, sorry dat ik er te weinig voor jullie ben geweest. Ik heb 
mijn best gedaan om alles zo goed mogelijk te combineren, maar ik heb ook 
wel ingezien dat niet alles te combineren is. Jullie zijn mijn grootste drive 
geweest om dit allemaal zo snel mogelijk af te ronden, zodat ik er meer voor 
jullie kan zijn.
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Chapter 10
Carla Meeuwis was born in the hospital of Hilversum, the Netherlands on April 
23rd, 1974. She graduated from secondary school in 1992 (Dudok College, 
Hilversum). After one year living in London as an Au-pair and student at Imperial 
College, she started her career as a X-ray technician (Gooi-Noord Hospital, 
Blaricum). She received her certificate in 1998 (BIGRA, Diemen).
In 2000 she was admitted to medical school at the university of Utrecht through 
decentralized selection. In 2005 she started her clinical research in MRI-guided 
breast biopsy at 3 tesla and published her first article one year later, before 
she obtained her medical degree in 2006. She continued her research as a 
PhD student at the Department of Radiology of the University Medical Center 
Utrecht under supervision of Prof. Mali and Dr. van den Bosch and a few years 
later at the Radboud University Nijmegen Medical Centre under supervision of 
Prof. Barentz, which resulted in this thesis.
During this period, in April 2007, she started her residency in Radiology at 
Rijnstate Hospital, Arnhem under supervison of Dr. Tj. Wiersma. From October 
2011 she will work as a radiologist in Rijnstate.
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